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Abstract 
Extraintestinal pathogenic E. coli (ExPEC) strains are the main etiologic agent of urinary tract 
infections (UTIs). ExPEC strains are also reported to be the most common cause of bacteraemia 
in the world, which often originate from UTI. The population structure of UTI E. coli strains 
is well described in the literature with increased prevalence of multidrug resistance driven by 
extended spectrum β lactamases (ESBLs). ESBL carriage and multidrug resistance of 
bacteraemia E. coli is on the increase yet little information is available about their population 
structure. With the aim to define the bacteraemia population structure, E. coli isolated from 
urine samples and blood cultures were collected from the Nottingham University Hospital NHS 
trust over a five month period. Isolates were tested for antimicrobial resistance, ESBL and 
virulence associated gene (VAG) carriage, and were typed by MLST. Significantly higher 
ESBL driven multidrug resistant strains were observed in the bacteraemia E. coli compared to 
the UTI isolates with no significant difference in the carriage of VAGs. Our data shows a 
reduction in population diversity within the bacteraemia isolates compared to the concomitant 
urine sample population resulting in a small number of dominant sequence types (STs) (ST131, 
ST73, ST95) which is associated with ESBL conferred multi drug resistance and not specific 
virulence genes. This suggests that the increased prevalence of ESBL carriage in ExPEC 
isolates is leading to a selective advantage in a small number of dominant lineages causing 
bacteraemia in patients. Comparative genome analysis of selected isolates belonging to the 
dominant ST (ST73) from bacteraemia and UTI was performed to investigate the presence of 
bacteraemia specific loci that may explain the loss of diversity in bacteraemia. No genomic 
regions were identified specific for the bacteraemia ST73 isolates other than ESBL carriage. 
Plasmid profiling of the ESBL positive isolates of this ST73 group from bacteraemia and UTI 
identified diverse types of plasmids spread between the strains. No specific genomic loci were 
identified specific for ESBL positive ST73 isolates from bacteraemia and UTI. This concludes 
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that random acquisition of ESBL plasmids by any ST73 E. coli may select for its progression 
to bacteraemia which is serious and debilitating. Our study provided a comprehensive snapshot 
of the E.coli population structure from contemporaneous clinical cases of UTI and bacteraemia. 
The large increase in multi-drug resistance in bacteraemia ExPEC populations compared to co-
circulating UTI populations is of clinical concern and represents a challenge in control and 
treatment of serious extra-intestinal E. coli infections. This provides an important clinical 
insight into how common E. coli STs could adapt to become dominant bacteraemia agents. 
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1.0 Introduction 
 
1.1 Escherichia coli 
Escherichia coli is a Gram negative, rod shaped, non-sporulating, facultative anaerobic 
bacterium belonging to the Enterobacteriaceae family. It is a natural commensal inhabitant of 
the intestines of humans, animals, lizards and birds (Tenaillon et al., 2010; Odonkor and 
Ampofo, 2013). E. coli is shed in the faeces of these natural hosts into the environment, where 
it can survive in soil, water or on food for several days. The successful survival of E. coli in 
these secondary environments is dependent upon several factors, such as the availability of 
nutrients and water, temperature, and acidity (van Elsas et al., 2011). Since E. coli is primarily 
an intestinal inhabitant survival outside the host is limited and the presence of E. coli in food 
or water is an indicator of faecal contamination or poor hygienic practices (Odonkor and 
Ampofo, 2013).      
E. coli is one of the first bacteria that colonize the human intestine, with initial colonization 
starting from early infancy. This occurs due to the transmission of E. coli from the mother to 
the new-born (Mandar and Mikelsaar, 1996; Watt et al., 2003), other studies have also reported 
a role for nursing staff in this early transmission (Bettelheim and Lennox-King, 1976). In fact, 
improved hygienic practices in hospitals not only delays the original transmission of E. coli to 
the infant, it also limits this early colonization (Nowrouzian et al., 2003). This commensal 
colonization occurs in the mucus of the epithelium of the large intestine, mainly the caecum 
and colon, where E. coli is shed in the lumen and excreted with the faeces (Tenaillon et al., 
2010).  
Unlike the intestinal commensal E. coli, intestinal pathogenic E. coli strains have acquired 
virulence factors enabling them to cause many serious diseases when present in the intestines 
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(Kaper et al., 2004). Classical examples of these strains are the enterohemorrhagic E. coli 
(EHEC), such as E. coli O157:H7, which have recently made the headlines for disease 
outbreaks of hemorrhagic colitis worldwide (Ateba and Mbewe, 2013). Another group of 
pathogenic E. coli strains can asymptomatically colonize the intestine. However, these E. coli 
strains have the ability to cause diverse and serious diseases outside of the intestinal tract. 
Hence, they are named extraintestinal pathogenic E. coli (ExPEC) strains. One subset of these 
strains is called uropathogenic E. coli (UPEC), which are the main etiologic agent of urinary 
tract infections (UTIs) (Johnson and Russo, 2002; Yamamoto, 2007). ExPEC strains are also 
reported as a common cause of bacteraemia and sepsis in the community (Johnson and Russo, 
2002). Other ExPEC strains are responsible for wound infections, surgical infections, neonatal 
meningitis and neonatal sepsis (Russo and Johnson, 2003; Wiles et al., 2008; Ron, 2010). 
 
1.2 Intestinal pathogenic E. coli 
Diarrhoea related mortality occurs worldwide, causing around 800,000 deaths every year (Liu 
et al., 2012). Children in developing countries of south Asia and sub Saharan Africa are the 
most affected, where it is estimated that one in ten children aged five and under die from 
diarrhoea (Liu et al., 2012). Intestinal pathogenic E. coli strains are major aetiological agents. 
Based on the pathogenesis and symptoms of intestinal pathogenic E. coli six major pathotypes 
have been described in the literature: Shiga toxin producing E. coli (STEC) which includes the 
subtype enterohaemorrhagic E. coli (EHEC), enteropathogenic E. coli (EPEC), 
enteroaggregative E. coli (EAEC), enteroinvasive E. coli (EIEC), enterotoxigenic E. coli 
( ETEC) and the diffusely adherent E. coli (DAEC) (Croxen et al., 2013). A comprehensive 
study was conducted to investigate the incidence and causative agents of diarrhoeal disease of 
children in sub Saharan Africa and South Asia, named the Global Enteric Multicenter Study 
(GEMS). This study reported that ETEC is one of the main four aetiological agents of severe 
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to moderate diarrhoea in these children. Furthermore, there was an increased risk of death due 
to diarrhoea in infants up to 11 months of age, which was highly associated with ETEC and 
EPEC (Kotloff et al., 2013).  
One important intestinal pathogenic E. coli subgroup is the serotype O157:H7 (O refers to the 
somatic lipopolysaccharide (LPS) antigens and H refers to the flagellar antigens), which has 
been reported to cause outbreaks of human diarrhoeal disease worldwide (Ateba and Mbewe, 
2013). Consumption of contaminated undercooked ground beef is the main cause of infection, 
but other food products have also been identified as sources of human infection (Ateba and 
Mbewe, 2013). The first two reported outbreaks were in 1982, associated with undercooked 
hamburgers (Riley et al., 1983). Since then numerous outbreaks have occurred resulting in an 
estimated 61 deaths in the United States according to the Centers for Disease Control and 
Prevention (CDC) (Santos Mendonça et al., 2012). The clinical manifestations resulting from 
E. coli O157:H7 infection can vary, from watery to severe bloody diarrhoea, or haemorrhagic 
colitis and life threatening haemolytic ureamic syndrome (HUS). As such these E. coli strains 
belong to the EHEC subgroup of E. coli. EHEC are considered a subset from STEC, because 
the disease is caused by the production of toxins called Shiga like toxins (referring to Shigella 
dysenteriae) that is responsible for damaging the intestinal lining and other organs, such as the 
kidney (Armstrong et al., 1996; Waswa et al., 2007; Smith et al., 2013). 
Another important intestinal pathogenic strain is EHEC O104:H4, which was responsible for 
the German gastroenteritis and HUS outbreak in 2011. This outbreak totalled 3816 cases in 
Germany with 22% suffering from HUS resulted in 54 deaths. Contaminated sprouts were 
identified as the vehicle of transmission (Frank et al., 2011; Buchholz et al., 2011). E. coli 
O104:H4 is an STEC pathotype producing Shiga toxin, but virulence factor profiling and whole 
genome sequencing revealed that the chromosomal backbone and some of its plasmids were 
related to the EAEC pathotype. These discoveries led to the conclusion that E. coli O104:H4 
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is a hybrid strain (Bielaszewska et al., 2011; Richter et al., 2014). This illustrates the plasticity 
and diversity of the E. coli genome and its continued evolution makes it very challenging to 
assign specific genes to a certain pathotype. New technologies such as whole genome 
sequencing are needed to produce more reliable and higher resolution typing of these 
pathogenic strains during outbreaks to discover the population dynamics of pathogenic E. coli. 
This would also enable the relationships of the E. coli strains to the host and environment to be 
studied, which would help improve our understanding of E. coli evolution (Croxen et al., 2013).   
 
1.3 Extraintestinal pathogenic E. coli (ExPEC) 
The ExPEC group of E. coli strains are able to stably colonize the intestinal tract without 
causing any enteric diseases. Based on multilocus enzyme electrophoresis (MLEE), which 
separates E. coli into four main phylogenetic groups (groups: A, B1, B2 and D)(Johnson and 
Russo, 2002), ExPEC belong to different phylogenetic groups than the commensal and enteric 
E. coli isolates. The ExPEC isolates belong to mainly group B2 and D, whilst the pathogenic 
intestinal E. coli are found in A, B1 or D, and the commensal E. coli belong to groups A or B1 
(Johnson and Russo, 2002). The acquisition of a combination of specific virulence factors 
(VFs), enables ExPEC to cause disease when present in organs or sites outside the intestines 
(Table 1.1). The most common disease caused by ExPEC are UTIs, however, ExPEC can also 
cause sepsis or bacteraemia, neonatal meningitis, pneumonia, surgical site infections, soft 
tissue infections and osteomyelitis (Russo and Johnson, 2003; Smith et al., 2007). 
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Table 1. 1: General classification of pathogenic types of E. coli in humans 
E. coli strains 
Pathogenic type MLEE 
phylogenetic 
groups (A, B1, 
B2 and D) 
Asymptomatic 
intestinal 
colonization 
Diarrhea 
 
Extraintestinal 
infection 
Commensal +++ ---- + A or B1 
Intestinal 
pathogen 
---- +++ ---- A, B1 or D 
ExPEC + ---- +++ B2 or D 
The level of pathogenicity is expressed as absent (----) or maximum (+++), adapted from 
(Johnson and Russo, 2002).   
 
ExPEC has been reported to constitute 20% of the faecal bacterial count of healthy individuals 
(Johnson and Russo, 2002), yet the exact origin of ExPEC colonization of the human intestine 
is unclear. Food was suggested as a source of ExPEC acquisition in several studies (Manges 
and Johnson, 2012). In a large sample study, 964 ExPEC isolates from UTI infections, healthy 
humans, broiler chicken, broiler chicken meat, pigs and pork were investigated for their 
phylogroups and acquisition of ExPEC related virulence associated genes (VAGs) (Jakobsen 
et al., 2010a; Jakobsen et al., 2010b). A total of 158 E. coli isolates from all sources (human, 
animals and animal products) were found to belong to phylogenetic group D with similar VAGs 
carried. The animal and animal-product isolates were also found to be able to cause UTI in a 
mouse infection model, suggesting animals and animal products may be possible routes of 
transmission (Jakobsen et al., 2010b ). A zoonotic origin of ExPEC has also been documented 
in several studies. E. coli strains isolated from chickens and turkeys with colibacillosis are 
called avian pathogenic E. coli (APEC) (Jakobsen et al., 2010a). APEC has reported similarity 
with ExPEC, suggesting the zoonotic potential of ExPEC (Jakobsen et al., 2010a). Studies have 
shown that APEC and ExPEC isolates can be found in the same MLEE phylogroup (B2) and 
that there is no significant difference in VAG carriage (Johnson et al., 2008). Furthermore, 
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human ExPEC were found to be able to cause disease in chickens, indicating that there is no 
host specificity in ExPEC (Moulin-Schouleur et al., 2007). A study conducted by Johnson and 
Clabots in 2006 surveyed members of a household (5 humans and a dog), in which a woman 
had suffered from a UTI caused by ExPEC, for the presence of ExPEC clones using random 
amplified polymorphic DNA (RAPD). During the study, the first woman’s ExPEC clone from 
acute cystitis was later extensively shared between all the members of the house, including the 
dog, suggesting host to host transmission and zoonosis (Johnson and Clabots, 2006). This 
conclusion was further investigated by Johnson et al. in 2008 with a larger study consisting of 
unrelated ExPEC isolates from humans (n = 55), dogs (n = 59) and cats (n = 16). 99% of the 
ExPEC belonged to the B2 phylogenetic group, but more importantly comparisons by macro 
restriction pulsed field gel electrophoresis (PFGE) revealed identical clones of ExPEC were 
shared between humans and dogs (Johnson et al., 2008), which further supported the zoonotic 
transmission hypothesis.                   
 
1.4 Pathogenesis of ExPEC in UTI and bacteraemia 
ExPEC strains are able to cause disease due to the acquisition of VAGs that encode for 
virulence factors (VFs), such as fimbrial adhesins, toxins, iron acquisition proteins, secreted 
proteins and capsule formation. These VFs have essential roles in causing disease by enabling 
the ExPEC to colonize and invade mucosal cells, acquire essential nutrients and disrupt the 
host immune system (Johnson and Russo, 2002; Skjot-Rasmussen et al., 2012). The essential 
role that these VFs play in the establishment of ExPEC infection has been well established. For 
example, Type 1 fimbriae, which are encoded by the fim operon, is a well characterized VF 
involved in the colonization of the bladder during UTIs (Wullt et al., 2002). Ascending UTIs 
and urosepsis are reported to require functional P pili encoded by pap genes (Wright et al., 
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2007). Acquisition of VFs associated with the pathogenicity island (PAI) is documented to 
increase ExPEC capability to cause systemic infections (Houdouin et al., 2006). 
Typically UTIs are initiated by the colonization of the intestinal flora by an ExPEC strain, 
followed by a periurethral or vaginal colonization period before entering the urethra and 
invading the bladder (Stamey and Timothy, 1976; Brumfitt et al., 1987). The hypothesis of 
rectal flora origins of ExPEC and periurethral colonization prior to UTI is supported by the 
presence of the same ExPEC isolates from both fecal and urine samples from an individual 
with a UTI (Moreno et al., 2008). After entering the urethra, ExPEC strains attach to the 
mannose structures of uroplakin receptors on the surface of bladder epithelial cells by type 1 
fimbriae (Sokurenko et al., 1998; Kau et al., 2005). This triggers apoptosis and exfoliation, 
with the bacteria moving to invade other cells and cause cystitis (Kaper et al., 2004). Type 1 
fimbriae also trigger the internalization of some of the attached bacteria into the bladder cell 
by binding to α3 and β1 integrin receptors (Eto et al., 2007). This causes the formation of 
intracellular bacterial communities (IBCs) with biofilm like properties to form within the 
infected bladder cells. This protects the bacteria from the host immune response and may act 
as a source of recurrent infections (Anderson et al., 2004). VFs encoding iron acquisition 
proteins are essential for the survival of ExPEC in the urinary tract during infection (Henderson 
et al., 2009). After the invasion of the bladder cells, released ExPEC may ascend to the kidney 
via the ureters. Attachment to the kidney epithelial cells is mediated by binding of P fimbriae 
to digalactoside receptors (Virkola, 1987; Kaper et al., 2004). Once the ExPEC has colonized 
the kidney other VFs, such as haemolysin and the secreted autotransporter toxin (SAT), are 
involved in damaging the renal epithelium, which results in pyelonephritis (Guyer et al., 2002; 
Dhakal and Mulvey, 2012). At this stage, some bacteria can penetrate the endothelial cells of 
the proximal tubules and gain access to the bloodstream resulting in bacteraemia (Kaper et al., 
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2004). This process of ascending infection from UTI to bacteraemia is termed urosepsis 
(Wagenlehner et al., 2007). Figure 1.1 displays the different steps of ExPEC pathogenesis. 
 
 
Figure 1. 1: Pathogenesis UTI caused by ExPEC. The figure displays the different stages of 
UTI caused by ExPEC starting by periurethral colonization, followed by invasion of the 
bladder and kidney epithelium and in some cases crossing the tubular epithelium resulting in 
bacteraemia (adapted from Kaper et al., 2004).  
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1.5 Main virulence factors associated with ExPEC 
ExPEC possess a variety of virulence factors (VFs) encoded by virulence associated genes 
(VAGs) which enables them to effectively colonize and invade host cells and evade host 
defences (Johnson and Stell, 2000). Most VFs are encoded by mobile genetic elements called 
pathogenicity islands (PAIs) (Hacker and Kaper, 2000). These PAIs have a G-C content 
different from that of the remainder of the chromosome and contain regions of mobile DNA 
sequences inserted adjacent to tRNA genes. Horizontal transfer between PAIs has contributed 
to their evolution and ExPEC may have several PAIs in their genome (Oelschlaeger et al., 
2002). PAIs may encode numerous VFs such as adhesins, iron uptake systems, toxins, capsules 
and secretion mechanisms (Hacker and Kaper, 2000).     
 
1.5.1 Adhesins:      
Adhesins are adhesive molecules that contribute to virulence by triggering host and bacterial 
cell signalling, promote delivery of bacterial products and promote invasion of host cells 
(Mulvey, 2002). Type 1 fimbriae are well characterized in animal infection models of UTIs. 
Encoded by fim genes, type 1 fimbriae promote attachment to host mucosal epithelial cells, 
survival and biofilm formation (Connell et al., 1996; Martinez et al., 2000; Anderson et al., 
2003). Attachment is mediated by the FimH subunit that binds to the manosylated glycoprotein 
uroplakin of the urothelium (Thumbikat et al., 2009). 
P fimbriae have been shown to have an essential role in human ascending UTIs and 
pyelonephritis (Väisänen et al., 1981). They promote the production of cytokines by attaching 
to the tissue matrix and mucosal surface (Leffler and Eden, 1980; Hedlund et al., 1999). P 
fimbriae are encoded by pap genes (A-K) and PapG recognizes the kidney epithelium 
glycosphingolipids (Wullt et al., 2000; Kaper et al., 2004). Type 1 fimbriae and P fimbriae 
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have been shown to play a synergistic role where P fimbriae enhances colonization of the 
tubular epithelium and type 1 fimbriae promotes colonization in the centre of the tubule 
resulting in complete obstruction of the nephron and pyelonephritis (Melican et al., 2011). 
S fimbriae and F1C fimbriae are involved in binding to human epithelial cell lines of the lower 
urinary tract and kidney (Mulvey, 2002; Bien et al., 2012). Fimbrial Dr and Afa adhesins are 
described to have a role in recurring cystitis and gestational pyelonephritis (Servin, 2005). Dr 
fimbrial adhesin binds to decay accelerating factor (DAF) and type IV collagen (Nowicki et al., 
2001) and displays a high tropism to the basement membrane of mouse renal interstitium 
(Goluszko et al., 1997). Afa adhesin shows a unique tropism to renal tissue and possibly plays 
a role in recurrent and chronic infection (Bouguénec, 2005). 
 
1.5.2 Capsule and lipopolysaccharide (LPS) 
The capsule and LPS are two of the surface virulence factors important for the survival of the 
bacterium. The capsule consists mainly of a polysaccharide structure covering the bacteria and 
protects it from complement mediated killing (Bien et al., 2012). K1 and K5 capsules have 
been described to help avoid the humoral immune response of the host by the molecular 
mimicking of tissue components and protect against killing by human serum (Buckles et al., 
2009; Bien et al., 2012). LPS is known to cause acute renal failure due to systemic response to 
cytokine production by the host immune response (Backhed et al., 2001), rather than expression 
of functional LPS receptors (TLR4) in the kidney in an animal model (Cunningham et al., 
2004). 
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1.5.3 Flagella 
Flagellated ExPEC causes 70 to 90% of all UTIs and pathogenesis is mediated by interactions 
between the flagella and the surface of host epithelial cells. It has been shown that flagellin acts 
as an invasin to invade the renal collecting duct in pyelonephritis (Pichon et al., 2009). It has 
also been shown that motility provided by the flagella is important for ascending UTIs and 
antibodies specific to the flagella have prevented the spread of infection to the kidneys (Schwan, 
2008). 
 
1.5.4 Toxins 
One of the most important secreted toxins by ExPEC during upper UTIs and pyelonephritis is 
the lipoprotein α-haemolysin (HlyA) (Bien et al., 2012). HlyA belongs to the RTX (repeats in 
toxin) toxin family that is present among many Gram-negative pathogens (Bhakdi, 1989). 
HlyA is a pore forming protein that has two different activities depending on its concentration 
(Laestadius et al., 2002). At high concentration α-haemolysin lyses erythrocytes, immune cells 
and mucosal epithelium that enables the bacteria to cross the mucosa, acquire host nutrients 
and iron reserves and damage the host defence system (Bien et al., 2012). At low concentration, 
α-haemolysin induces apoptosis of host immune cells such as lymphocytes, neutrophils, and 
renal cells which results in the exfoliation of host epithelial cells (Chen et al., 2006; Smith et 
al., 2006). About 50% of complicated renal infections are linked to HlyA production and may 
lead to permanent renal scarring (Jakobsson et al., 1994).  
Cytotoxic necrotising factor 1 (CNF1) is reported to induce formation of actin stress fibres and 
Rho GTPase dependant membrane ruffle formation resulting in cell invasion. It is reported in 
one third of pyelonephritis isolates showing invasion of the kidneys (Landraud et al., 2000). It 
is also reported to cause apoptosis and exfoliation of epithelial cells in the bladder (Mills et al., 
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2000). Secreted autotransporter toxin (SAT) is toxic to bladder and kidney cell lines indicating 
a role in pyelonephritis (Guyer et al., 2002). 
 
1.5.5 Iron acquisition systems 
ExPEC have different types of iron acquiring mechanisms to be able to survive and compete 
with host cells. They use iron chelators called siderophores, such as yersiniabactin (fyuA) and 
aerobactin (iutA) (Johnson et al. 2007). Yersiniabactin is also described to have a role in biofilm 
formation and ascending UTIs in a mouse infection model (Hancock et. Al., 2008; Spurbeck 
et. Al., 2012). Studies have shown an essential role of aerobactin in ExPEC iron acquisition in 
vivo (Garcia et. Al., 2011).                    
 
1.6 Incidence of UTI due to ExPEC 
In clinical practice, bacterial infectious diseases are the most common causes of UTI (Foxman, 
2003). In USA, the annual incidence of UTIs is estimated to be 12% in women and 3% in men 
(Foxman, 2003). E. coli is the predominant causative agent of UTIs (Yamamoto, 2007). The E. 
coli strains responsible for causing UTIs are described as a pathotype of ExPEC and termed as 
UPEC. UPEC are characterised by the acquisition of a set of VFs (Johnson and Russo, 2005). 
UPEC accounts for more than 68% of community acquired UTI and more than 35% of 
nosocomial UTI infections (Bouza et al., 2001; Kashef et al., 2010). The complications 
associated with UTIs are cystitis, pyelonephritis and bacteraemia (Warren et al., 1999). UPEC 
is reported to account for up to 90% of acute cystitis and quarter of a million cases of 
pyelonephritis in the USA per annum (Foxman, 2003). Worldwide UPEC is estimated to be 
responsible for 130 to 175 million cases of uncomplicated cystitis and 5.4 million cases of 
pyelonephritis every year (Russo and Johnson, 2003). In a UK study conducted by Woodford 
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et al. in 2004, E. coli causing UTI were collected from 42 UK centres, 24% of which were 
community acquired. Nosocomial E. coli UTI which are the most rapidly spreading cause of 
community acquired UTIs have a significant economic impact in the UK (Plowman et al 2001; 
Woodford et al., 2004).  
 
1.7 Increasing incidence of bacteraemia due to ExPEC 
The incidence of blood stream infection (bacteraemia) is becoming more common and is 
associated with increased levels of mortality (Wagenlehner et al., 2007; Jensen et al., 2010). In 
the USA, around 250,000 cases of bacteraemia are recorded annually and considered one of 
the leading causes of death with a mortality rate of 18% (Marschall et al., 2008). Bacteraemia 
due to E. coli infection, which can be community or hospital acquired, is increasingly reported 
worldwide (Ron, 2010). E. coli bacteraemia infections account for 17 to 37% of bacteraemia 
cases globally (Russo and Johnson, 2003), and is associated with a high mortality rate 
(Laupland et al., 2008). In the UK, the Health Protection Agency reported that E. coli 
bacteraemia infections between 2008 and 2010 increased by 33%, overtaking bacteraemia 
caused by methicillin resistant Staphylococcus aureus (MRSA) (Wilson et al., 2011). In 
response, the Department of Health extended mandatory reporting of E.coli bacteraemia 
infections in 2011, with the aim of reducing the rate of infections through increased awareness 
of circulating bacteraemia causing E. coli (Underwood et al., 2011). Analysis of the Guy’s and 
St Thomas’ NHS Foundation Trust during the year 2010 revealed that E.coli was isolated from 
29% of total bacteraemia infections, of which the majority (63%) were community acquired 
(Underwood et al., 2011). According to the latest quarterly epidemiological commentary 
released by the Public Health England on December 2014, E. coli bacteraemia is still on the 
increase since 2011 with a rate of 70 persons per 100 000 of population affected (Table 1.1) 
(Public Health England, 2015b). 
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Table 1.1: Table of quarterly epidemiological commentary of E. coli bacteraemia by 
Public Health England.  
Year and quarter 
(Q) 
Total E.coli bacteraemia 
reports 
Rate (per 100,000 
population) 
2011         Q3 
 
                 Q4 
 
8275 
8098 
61.82 
60.50 
2012        Q1 
 
                 Q2 
 
                 Q3 
 
                 Q4 
7698 
8074 
8676 
7957 
57.88 
60.71 
64.52 
59.18 
2013        Q1 
 
                 Q2 
 
                 Q3 
 
                 Q4 
7602 
8193 
9079 
8623 
57.24 
61.02 
66.87 
63.51 
2014        Q1 
 
                 Q2 
 
                 Q3 
8380 
8886 
9473 
63.09 
66.17 
69.77 
The table describes the Quarterly counts and rates of E. coli bacteraemia from the mandatory 
reports of E. coli bacteraemia by Public Health England (Public Health England, 2015b). 
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Studies have reported that E. coli is also the most frequent organism isolated from septicaemia, 
which has developed following UTI (McBean and Rajamani, 2001). A study in the North West 
of England reported that E. coli accounts for 74.9% of the Gram negative bacteraemia samples 
of UTI origin (Al-Hasan et al., 2010). The Guy’s and St Thomas’ NHS Foundation Trust 
reported that 49% of the E. coli bacteraemia were of UTI origin (Underwood et al., 2011). The 
association of E. coli bacteraemia with a UTI origin is still significant in the UK. The last 
annual epidemiological commentary released by Public Health England in 2014 reported that 
50.4% of community acquired E. coli bacteraemia and 39.6% of the hospital acquired E. coli 
bacteraemia were of UTI origin (Figure 1.2) (Public Health England, 2015a).  
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Figure 1. 2: Distribution of sources of E. coli bacteraemia in the UK in 2014. The figure obtained from the annual epidemiological commentary 
released by Public Health England on July 2014 (Public Health England, 2015a). A: UTI (dark green) accounts for 50.4% of community acquired 
bacteraemia (cultures obtained within 2 days of admission). B: UTI accounts for 39.6% of hospital acquired bacteraemia (cultures obtained in after 
2 days of admission).   
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1.8 Extended spectrum β-lactamases (ESBLs) 
ESBLs are defined as class A or D β-lactamases, which are able to inactivate oxyimino 
cephalosporins by hydrolytic activity with an active site serine, and inhibited generally by β-
lactamase inhibitors such as sulbactam, tazobactam or clavulanic acid (Bush et al., 1995). Most 
ESBLs are encoded on large plasmids that can be transferred between strains, or even between 
bacterial species (Jacoby and Medeiros, 1991). ESBLs have evolved from amino acid 
substitutions in plasmid enzymes Temoniera (TEM, encoded by bla-TEM), sulfhydryl variable 
(SHV, encoded by bla-SHV) and oxacillinase (OXA, encoded by bla-OXA). A novel, non TEM, 
non SHV, non OXA lineage has also developed, first discovered in Germany named CTX-M 
(CefoTaXime active in Munich, encoded by bla-CTX-M) (Knothe et al., 1983; Kliebe et al., 1985; 
Sirot et al., 1987; Sougakoff et al., 1988). The intrinsic mutations in these enzymes caused 
major amino acid substitutions and alterations in the structure of the active site which increased 
their hydrolytic activities against third generation cephalosporins. Thus in addition to resistance 
against penicillins, first and second generation cephalosporins, resistance to oxyimino 
cephalosporins (ceftazidime, cefotaxime, ceftriaxone) and monobactams such as aztreonam is 
also observed. The Cephamycins and carbapenems (meropenem, imipenem, ertapenem) on the 
other hand are generally unaffected (Stürenburg and Mack, 2003). 
 
1.9 Increasing incidence of ESBL producing E. coli    
The incidence of CTX-M has rapidly surpassed that of the classical TEM and SHV ESBLs 
worldwide (Livermore et al., 2007). CTX-M ESBL producing members of the 
Enterobacteriaceae family are to cause hospital and community acquired infections (Pitout et 
al., 2005). However, since 2000 CTX-M producing E. coli has emerged as a leading cause of 
community acquired UTI globally; this has been termed the CTX-M pandemic (Cantón and 
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Coque, 2006; Rossolini et al., 2008). CTX-M-15 is the CTX-M ESBL most widely distributed 
worldwide, since the first report in 2001(Karim et al., 2001). Since then, CTX-M-15 producing 
multidrug resistant (MDR) E. coli is emerging as an important cause of community, or hospital 
acquired infections worldwide (Woodford et al., 2004; Coque et al., 2008; Nicolas-Chanoine 
et al., 2008).  
An established E. coli multilocus sequence typing (MLST) scheme is currently used worldwide 
to study the population dynamics of pathogenic ExPEC strains. Several MLST sequence types 
(STs) such as ST95, ST73, ST131, ST69, ST127 represent well characterized, commonly 
isolated human ExPEC strains (Lau et al., 2008b, Johnson et al., 2008b, Johnson et al., 2008a, 
Mora et al., 2009). The most well recognised ST is E. coli ST131, which is increasingly 
reported in cases of UTIs worlwide (Nicolas-Chanoine et al., 2008). Recently, E. coli ST131 
has caused increasing concern in the health care community, as it is resistant to most commonly 
used antibiotics and associated with CTX-M-15 carriage (Lau et al., 2008a; Nicolas-Chanoine 
et al., 2008; Pitout and Laupland 2008). E. coli ST131 is a major contributor to the CTX-M 
pandemic (Totsika et al., 2011). The bla-CTX-M gene is carried on IncFII plasmids in E. coli 
ST131 (Coque et al., 2008), however other types of plasmids such as FII, FIA and FIB were 
also associated with ST131 and ExPEC ESBL carriage (Rogers et al., 2011). E. coli ST131 is 
also frequently resistant to fluoroquinolones (Johnson et al., 2009; Johnson et al., 2010). In 
addition to mutations in chromosomal gyrA and parC gene, fluoroquinolone resistance can be 
mediated by plasmid encoded quinolone resistance genes qnr (A, B and S) and aac(6’)-Ib-cr 
(aminoglycosides/fluoroquinolone acetyltransferase) (Baudry et al., 2009). Many studies in the 
UK have reported a high prevalence of CTX-M-15 producing ST131 E. coli in hospital and 
community onset UTIs (Gibreel et al., 2011; Croxall et al., 2011). In addition to ST131, other 
sequence types were reported to have a role in the worldwide distribution of CTX-M, such as: 
ST38, ST405 and ST648 (Peirano and Pitout, 2010). 
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Reports of multidrug resistant ESBL producing E. coli are on the increase worldwide. A 4 year 
study in Spain investigating incidence of bacteraemia reported that 70% of E. coli bacteraemia 
isolates produced a CTX-M type ESBL, of which 46% were of urinary origin (Rodriguez-Bano 
et al., 2006). In China, 24.2% of bacteraemia E. coli strains were ESBL positive (To et al., 
2013). In Turkey, ESBL producing E. coli accounted for 38.9% of E. coli bacteraemia cases 
between 2007 and 2011 (Kaya et al., 2013). The increasing prevalence of ESBL producing 
bacteraemia E. coli raises concerns and challenges in the medical community (Peirano and 
Pitout 2010). A study was performed to investigate and compare ESBL producing to non-ESBL 
producing bacteraemia E. coli isolates between June 2003 to November 2005 in the UK 
(Melzer and Petersen, 2007). ESBL producing E. coli were reported in 6.6% of community and 
in 26% of hospital acquired bacteraemia infections where the most common source was UTI’s, 
which accounted for 67% of the cases (Melzer and Petersen, 2007). This study revealed that a 
significantly higher percentage of patients with ESBL producing E. coli bacteraemia (60.8%) 
died compared to the percentage of deaths in patients resulting from a non-ESBL producing E. 
coli bacteraemia (23.7%) (Melzer and Petersen, 2007). In a more recent investigation of E. coli 
bacteraemia in the UK by Wilson et al. (2011), a significant proportion of ESBL producing E. 
coli isolates were identified as the infecting agents. ESBL producing E. coli isolates were 
reported in 16% of E. coli bacteraemia cases, 55% of which were of community onset and 35% 
were of urinary origins (Wilson et al., 2011).        
 
1.10 Population structure of ExPEC 
MLST is a molecular typing method based on the DNA sequencing of approximately 500 bp 
from seven unlinked housekeeping genes, which are used to identify bacterial strains (Maiden 
et al., 1998). Due to the reproducibility and comparability between different laboratories, 
MLST is considered the gold standard for ExPEC genotyping (Tartof et al., 2005). The 
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‘Achtman’ scheme is the established MLST typing scheme for E. coli (Wirth et al., 2006), and 
the database is available via a publically accessible website 
(www.mlst.warwick.ac.uk/mlst/dbs/Ecoli). In the MLST database, strains that share the same 
seven housekeeping gene alleles are identified as a unique ST (Wirth et al., 2006). A minimum 
spanning tree (MST) of the structure of the ExPEC population using the results from the MLST 
scheme as of January 2011 was produced by Köhler and Dobrindt (2011) in Figure 1.3. The 
MST uses eBURST algorithms to identify strains which differ in only one of the seven 
housekeeping gene alleles (single locus variants) into groups called a clonal complex (CCs) 
(Feil et al., 2004). The MST contained 3454 entries consisting of 32% ExPEC isolates (1117 
entries), 27% intestinal E. coli isolates (922 entries), 16% non-pathogenic isolates (535 enteries) 
and the rest are isolates that do not belong to any of these groups. Of the total of 1859 STs in 
the MLST database (as of January 2011), 114 CCs were determined consisting of 1197 STs 
(containing 2610 entries). The clinical source of the isolates was mapped on the MST and the 
vast majority of the ExPEC STs and CCs also included other pathotypes and non-pathogenic 
strains (Figure 1.3). 
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Figure 1. 3: Minimum spanning tree presenting the population structure of ExPEC 
isolates. The Figure was produced by Köhler and Dobrindt, (2011) with reference to Achtman 
MLST database (www.mlst.ucc.i.e./mlst/dbs/Ecoli) as of January 2011 (Köhler and Dobrindt, 
2011). In the Figure (inf) refers to clinical isolates from different infections and (IPEC) refers 
to intestinal pathogenic E. coli. The main STs and CCs of ExPEC determined by the circle on 
top are enlarged with pie charts mapping the clinical source. The size of the pie chart reflects 
the number of isolates included in the STs or CCs. 
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CC10 is located in the middle of the MST. It represents the largest CC in the database including 
many intestinal pathogenic E. coli, non-pathogenic E. coli, non-defined isolates, and only a 
small proportion of ExPEC isolates. To the right of the CC10 are CCs comprised of 
predominantly intestinal pathogenic E. coli and non-pathogenic isolates and others. At the far 
right of the tree is CC69, which mainly consists of ExPEC isolates. On the left of CC10 are the 
STs and CCs that include mainly ExPEC and non-pathogenic isolates. These major ExPEC 
CCs and STs (95, 73, 131, 127, 17, 14, 144 and 12) are extensively reported in the literature as 
pathogenic ExPEC STs (Tartof et al., 2005; Wirth et al., 2006; Zdziarski et al., 2008; Peirano 
and Pitout, 2010; Croxall et al., 2011; Rogers et al., 2011;). These STs and CCs comprise the 
largest number of isolates in the Achtman MLST database, 47.7% of CC95 are ExPEC isolates, 
which comprise 11.6% of the total ExPEC in the database, 62.7% of CC73 are ExPEC isolates, 
which comprise 8.4% of the total ExPEC in the database and 66.3% of CC131 are ExPEC 
isolates which comprise 7.5% of ExPEC in the database. Almost all the isolates in the database 
of this ExPEC branch of the MST belongs to the B2 phylogenetic group which confirms the 
ExPEC pathotype, while ST69 isolates belongs to phylogenetic group D hence they are located 
to the far right of the MST (Köhler and Dobrindt, 2011). The main ExPEC STs and lineages 
such as (ST95, ST73, ST131) are well characterized in the literature in terms of the acquisition 
of VFs, which enables them to be virulent extraintestinal pathogens compared to the other CCs 
in the E. coli population (Manges et al., 2008; Martinez-Medina et al., 2009; Johnson et al., 
2010). 
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1.11 Most common STs of ExPEC 
1.11.1 E. coli ST131 
In the early 2000s PFGE analysis was performed on two E. coli isolates that produced CTX-
M-15 ESBL, one from Canada and one from the UK (Woodford et al., 2004; Pitout et al., 2007). 
The PFGE identified more than 80% pulsotype cluster similarities, and were named clone A in 
the UK and clone 15A in Canada (Woodford et al., 2004; Pitout et al., 2007). With the 
development of MLST these strains were then identified as belonging to ST131, which is 
characterized by serotype O25b:H4 and MLEE phylogenetic group B2 (Coque et al., 2008; 
Nicolas-Chanoine et al., 2008). Other serotypes have also been included in ST131, such as 
O16:H5 and non typable O antigen (Matsumura et al., 2012; Dahbi et al., 2013; Olesen et al., 
2013). In Australia, an ST131 strain serotype O157 was also reported (Platell et al., 2011a). 
Most of the increased antibiotic resistance in ExPEC infections, especially ESBL producing 
and fluoroquinolone resistant ExPEC, is attributed to spread of ST131 (Rogers et al., 2011). 
Resistance is mediated mainly by ESBL type CTX-M-15 encoded by blaCTX-M-15 gene on 
plasmids while fluoroquinolone resistance is due to mutations in chromosomal genes gyrA and 
parC (Cagnacci et al., 2008; Nicolas-Chanoine et al., 2008; Johnson et al., 2013). Other CTX-
M types are also associated with ST131, such as CTX-M-2, CTX-M-3 and CTX-M-9 (Suzuki 
et al., 2009; Mora et al., 2010).   
The origins of ST131 are unknown. Some studies reported that ST131 strains were identified 
as early as 1994 in France (Clermont et al., 2009). ST131 E. coli can be isolated from 
community and hospital infections, but the source of infection is not well characterised. In a 
study at a general hospital in San Francisco between 2007 and 2010, ST131 E. coli infections 
were identified in 23% of E. coli bacteraemia patients, but more than 70% from patients within 
48 hours of admission, which indicates community acquired origins (Adams-Sapper et al., 
2013). In the UK, ST131 E. coli was the most dominant ST associated with ESBL CTX-M-15 
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(Croxall et al., 2011). Intestinal carriage of ST131 was also reported in livestock, wild and 
domestic animals (Platell et al., 2011b). Several main VAGs are described in association with 
ST131 clinical isolates, iha (siderophore associated), fimH (type I fimbriae), sat (toxin), 
fyuA/irp2 and iutA/iucD (siderophore associated), kpsM II (capsule), usp (uropathogenic 
specific protein), traT (serum resistance), ompT (protease of outer membrane) and malX 
(pathogenicity island) (Johnson et al., 2010; Platell et al 2011a; Matsumura et al., 2012; Dahbi 
et al., 2013). 
 
1.11.2 E. coli ST69 
In California between January 1999 and 2000, 255 E. coli strains were isolated from 228 
clinical cases of community acquired UTIs (Manges et al., 2001). Of these, 55 isolates were 
found resistant to trimethoprim-sulphamethazole. When analysed by enterobacterial repeat 
intergenic consensus (ERIC2) PCR fingerprinting, 51% of these resistant isolates were found 
to have the same banding pattern (Johnson and O'Bryan, 2000) and were designated the name 
clonal group A (CgA) (Manges et al., 2001). This clonal group was then identified as ST69 
complex by MLST (Tartof et al., 2005). ST69 E. coli strains belong to the phylogenetic group 
D and include many serotypes of O antigen variants including: O11, O15, O73, O77, O86, 
O125ab and O25b (Manges et al., 2008; Blanco et al., 2011; Colomer-Lluch et al., 2013; Skjøt-
Rasmussen et al., 2013). ST69 strains are isolated worldwide from UTIs and bacteraemia from 
both hospital and community acquired cases (Dias et al., 2009; Johnson et al., 2009; Adams-
Sapper et al., 2013). Most ST69 have a class I integron containing the arrangement of (dfrA17 
– aadA5) gene cassette encoding dihydrofolate reductase and aminoglycoside 
adenyltransferase that makes them multidrug resistant (Solberg et al., 2006; Ajiboye et al., 
2009). In a study of E. coli bacteraemia isolates collected in San Francisco between 2007 and 
2010, ST69 complex was found to be the fourth most prevalent ExPEC ST after ST131, ST95 
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and ST73 (Adams-Sapper et al., 2013). 83% of all these ST69 E. coli cultures were obtained 
less than 48 hours after admission, which suggests they are of community acquired origin. 
ST69 E. coli isolates may have nonhuman origins as they have been isolated from pork, chicken 
and beef (Ramchandani et al., 2005; Vincent et al., 2010; Jakobsen et al., 2011). Nonhuman 
ST69 isolated from chicken meat were found to be as pathogenic as human ST69 isolates and 
caused UTIs in a mouse infection model, which may suggest a zoonotic origin of ST69 
(Jakobsen et al., 2010). A variety of VAGs are found associated with ST69 complex isolates,  
afa/dra (Dr adhesins), K1 and kpsMT (capsule), papA and papG alleles (P fimbriae adhesion) 
and sfa/focDE (S and FIC fimbriae) (Johnson et al., 2002; Johnson et al., 2005). 
 
1.11.3 E. coli ST95 
E. coli ST95 strains belong to phylogenetic group B2 and include serotypes O1/O2/O18:K1:H7 
(Weissman et al., 2006). ST95 E. coli K1 capsule serotypes are associated with neonatal 
meningitis (Glode et al., 1977; Tivendale et al., 2010). ST95 E. coli strains also include APEC, 
which cause colibacillosis in wild and domestic birds (Blanco et al., 1998; Mora et al., 2009). 
ST95 E. coli isolates were the second most prevalent ST complex isolated from bacteraemia E. 
coli infections from a general hospital in San Francisco between 2007 and 2010 (Adams-Sapper 
et al., 2013). In France, ST95 complex was the most common E. coli ST isolated from blood 
and ascitic fluid between 1997 and 2006 (Bert et al., 2010). ST95 complex isolates are 
characterised by low multidrug resistance frequency. More than half of the ST95 E. coli isolates 
were sensitive to all antibiotics in a San Francisco study (Adams-Sapper et al., 2013). One of 
four ST95 E. coli isolated from UTIs was found resistant to any antibiotic in Montreal between 
2007 and 2009 (Manges et al., 2008). In North-West England, ST95 E. coli isolates from UTIs 
presented the lowest antibiotic resistance score of the nine common E. coli ST complexes 
reported (Gibreel et al., 2011). ST95 E. coli complex may have zoonotic potential, as ST95 
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isolates from avian colibacillosis were able to cause neonatal meningitis in a rat infection model 
(Tivendale et al., 2010). At the same time, human ST95 E. coli isolates from neonatal 
meningitis were able to cause colisepticemia in poultry (Moulin-Schouleur et al., 2007). Many 
VAGs are described for ST95 isolates which encode for type I fimbriae (fimH), P fimbriae 
(papG), siderophore system (iucD), capsule (kpsM II and II-K1), serum resistance (traT), 
pathogenicity island (malX) and uropathogenic specific protein (usp) (Manges et al., 2008; Bert 
et al., 2010; Mora et al., 2013). 
 
1.11.4 E. coli ST73 
E. coli ST73 isolates belong to phylogenetic group B2 and are only associated with serotype 
O6:H1 (Johnson et al., 2008; Martinez-Medina et al., 2009). In the UK, ST73 E. coli isolates 
were the most common ST from UTI (Gibreel et al., 2011) and bacteraemia (Horner et al., 
2014), and second dominant in UTI (Croxall et al., 2011). It was the third most common E. coli 
ST isolated from bacteraemia in a general hospital in San Francisco and ten hospitals in France 
(Brisse et al., 2012; Adams-Sapper et al., 2013). In Egypt, ST73 E. coli isolates were reported 
as one of the most common ExPEC STs associated with CTX-M-15 ESBL carriage (Fam et al., 
2011). The pyelonephritis reference strain E. coli CFT073, which is used in animal models and 
ExPEC virulence studies, is an ST73 strain isolated from the blood of a woman with 
pyelonephritis (Johnson et al., 2008). Prototypic VAGs of ExPEC associated with ST73 E. coli 
isolates encode for P fimbriae adhesion (papC, papEF, papG), S and FIC fimbriae adhesin 
(sfa/foc), type I fimbriae (fimH), yersiniabactin receptor (fyuA), capsule (kpsM II) and outer 
membrane protease (ompT) (Martinez-Medina et al., 2009; Bert et al., 2010). 
. 
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1.11.5 E. coli ST10 
E. coli ST10 strains and the closely related STs in ST10 CC belong to phylogenetic group A, 
which is associated with colonization of the human intestine. There are numerous serotypes 
associated with ST10. They are usually associated with low virulence and antibiotic 
susceptibility (Manges and Johnson, 2012). Few ST10 E. coli isolates have been associated 
with human disease, ESBL carriage and livestock (Oteo et al., 2009; Cortes et al., 2010; Peirano 
et al., 2012). In the Netherlands, ST10 E. coli were isolated from human and poultry blood 
cultures and were CTX-M-1 producers (Leverstein-van Hall et al., 2011). In Canada, multidrug 
resistant ST10 E. coli strains were isolated from human clinical samples, chickens faeces, retail 
chicken, pig faeces and pork meat (Bergeron et al., 2012). 
                                     
1.12 Aims of the project 
Bacteraemia infections as a result of multi-drug resistant extra-intestinal pathogenic E. coli 
have overtaken MRSA as the leading cause of health care associated blood stream infections 
in the world. More concerning is the huge rise in associated antimicrobial resistant infections 
as a result of the increasing prevalence of ESBL carriage among ExPEC isolates. Despite ESBL 
ExPEC infections now being a major global health threat, and ESBL carriage in bacteraemia 
ExPEC isolates being on the increase, there are still few studies on the population genetics of 
ExPEC bacteraemia isolates, in comparison to the abundance of literature on urinary tract 
infections, which are often the source of such E. coli bacteraemia. Furthermore numerous 
studies have demonstrated the enormous diversity within ExPEC populations associated with 
UTIs, but with little information on bacteraemia isolates. We sought to define the ExPEC 
population causing bacteraemia by collecting clinical isolates from the largest clinical 
microbiology laboratory service provider in the United Kingdom, the Nottingham University 
29 
 
Hospitals microbiology laboratory. Isolates were collected over a 5 month period, alongside 
urine sample isolates from the concomitant period to provide a reference point for circulating 
ExPEC strain population characteristics. The general aims of the study are: 
A) Screening and testing the clinical E. coli isolates from bacteraemia and UTIs for antibiotic 
resistance, ESBL and virulence gene carriage. 
B) Determining the genetic structure of bacteraemia and UTI E. coli populations by MLST. 
C) Comparing the two populations of E.coli isolates to provide a comprehensive snapshot of 
the current ExPEC genetic epidemiology in bacteraemia and UTIs in the region. 
D) Determining and comparing the gene content of a selected group of isolates from 
bacteraemia and UTIs to identify unique genetic loci, or regions specific for bacteraemic E. 
coli. 
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2.0 General Materials and Methods 
 
2.1 Collection of isolates 
In the period between March 2011 and July 2011, one hundred and forty E.coli isolates from 
clinical cases of bacteraemia and another one hundred and twenty five E.coli isolates from 
clinical cases of UTI were collected from the Clinical Microbiology Department at Nottingham 
University Hospital. The selection of the cases was performed at random with no additional 
information except the age of the patients. Isolates were assigned a serial number as they were 
collected with letter B for bacteraemia clinical isolates and letter U for UTI clinical isolates. 
On average, 10 E.coli UTI isolates and 5 E. coli bactereamia isolates were collected per week. 
 
2.1.1 Bacterial cultures maintenance and storage 
All the E.coli isolates from clinical cases of bacteraemia and UTIs were collected as nutrient 
agar slopes and were sub-cultured on Cystine-Lactose-Electrolyte Deficient Agar (CLED, 
Sigma-Aldrich) to confirm purity of the isolates. Pure cultures were assigned a number with 
letter B for bacteraemia isolates, or U for UTI isolates. Stocks of all the bacterial cultures were 
maintained in 1ml of Luria Bertani Broth (LB) and 20% glycerol (Fisher Scientific) and stored 
at -80˚C. 
 
2.1.2 Species Confirmation of Bacterial Cultures 
All isolates were confirmed as E. coli species by API 20E identification kit (BioMérieux). 
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2.2 Culture media 
 
2.2.1 Luria-Bertani (LB) Agar 
The media was ordered from Sigma-Aldrich. It consists of 5g/L yeast extract, 10g/L sodium 
chloride, 10g/L tryptone, and 15g/L granulated agar. 40g of LB agar was dissolved in 1L 
distilled water (dH2O) and sterilised by autoclaving for 15 minutes at 121°C. 
 
2.2.2 LB broth 
The media was ordered from Sigma-Aldrich. It consists of 5g/L yeast extract, 10g/L sodium 
chloride, 10g/L tryptone, and 15g/L granulated agar. 20g of LB broth was dissolved in 1L 
(dH2O) and sterilised by autoclaving for 15 minutes at 121°C.  
 
2.2.3 Cystine Lactose Electrolyte Deficient (CLED) agar 
The media was ordered from Oxoid Limited UK. It consists of 0.128g/L L-cystine, 10g/L 
lactose, 4g/L tryptone, 0.02g/L bromothymol blue and 4g/L peptone. 36.2g was dissolved and  
sterilised by autoclaving for 15 minutes at 121°C. 
 
2.3 Antibiotic Susceptibility profiles 
Antibiotic resistance tests of all the E. coli isolates from bacteraemia and UTI samples were 
performed with reference to the protocol for standardized disc susceptibility testing method 
provided by The British Society for Antimicrobial Chemotherapy (BSAC) (Andrews and 
Howe, 2011). A panel of ten antibiotics were selected described in Table 2.1. 
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Table 2. 1: Antibiotics details used in the standardized disc susceptibility test 
Antibiotic Group Antibiotic Name Disc concentration (µg) 
Aminoglycoside Gentamicin (GM) 10µg 
Third Generation 
Cephalosporin 
Ceftazidime (CAZ)  30µg 
Carbapenem Meropenem (MEM)  10µg 
Combination of penicillins 
and β-lactamase inhibitor 
Piperacillin-Tazobactam (PTZ) 75/10µg 
Combination of β-
lactamase inhibitors 
Co-Amoxiclav (Augmentin) 
(AUG)  
20/10µg 
Dihydrofolate reductase 
inhibitors 
Trimethoprim (TM)  2.5µg 
Second generation 
fluoroquinolone 
Ciprofloxacin (CIP)  1µg 
First generation 
cephalosporin  
Cefradine (CRD)  30µg 
Miscellaneous Nitrofurantoin (NI)  200µg 
Penicillins Ampicillin (AP)  10µg 
  
All the E. coli isolates were tested for their ability to produce extended spectrum β lactamases 
(ESBL) by using ESBL combination discs provided by MAST GROUP Ltd. Control Strains E. 
coli NCTC 13353, E. coli NCTC 13351, E. coli NCTC 10418 and Klebsiella pneumoniae 
NCTC 13368 were used as controls. The isolates were sub-cultured into LB agar and incubated 
overnight at 37ºC. Inoculums were prepared by transferring four identical colonies of each 
isolate into saline solution to yield a density equal to 0.5 McFarland Standard. Cotton swabs 
were dipped in the inoculums and used to inoculate Iso-sensitest agar plates within 15 minutes 
of preparation of the inoculums. A maximum of six antibiotic discs were applied per plate and 
the cultures were incubated at 37ºC for 18-20 hours. Zones of inhibition of growth around the 
antibiotic discs for each isolate were then measured and referred to the BSAC tables to 
determine their antibiotic sensitivity. 
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2.4 PCR screening of extended-spectrum β-lactamase (ESBL) encoding 
genes 
Bacterial genomic DNA was extracted using GenElute extraction kits (Sigma-Aldrich). PCR 
detection of ESBL encoding genes blaOXA, blaCTX-M, blaTEM and blaSHV was performed using 
previously described multiplex primers (Fang et al., 2008). Control cultures were used to 
confirm the validity of the primers. These control strains were NCTC 13353 E. coli (blaOXA, 
blaCTX-M-15, and blaTEM), NCTC 13351 E. coli (blaTEM-3) and NCTC 13368 Klebsiella 
pneumoniae (blaTEM and blaSHV-18). The primer sequences, the PCR reagents concentrations 
and the PCR conditions are described in Table 2.2, Table 2.3 and Table 2.4 respectively. PCR 
products were run on 2% agarose gels at 90 volt for 50 minutes and the ESBL gene carried was 
determined for each isolate. All the CTX-M positive PCR products of the isolates were 
sequenced. The CTX-M type of all the isolates in this study was CTX-M-15.  
Table 2. 2: Multiplex ESBL PCR primer sequences and their product size  
Target 
Gene 
Forward and reverse primer names and sequences 
Product 
size 
blaSHV 
shvF 5'-CTTTATCGGCCCTCACTCAA-3' 
shvR 5'-AGGTGCTCATCATGGGAAAG-3' 
237 bp 
blaTEM 
temF 5'-CGCCGCATACACTATTCTCAGAATGA-3' 
temR 5'-ACGCTCACCGGCTCCAGATTTAT-3' 
445 bp 
blaCTX-M 
ctxmF 5'-ATGTGCAGYACCAGTAARGTKATGGC-3' 
ctxmR 5'-TGGGTRAARTARGTSACCAGAAYCAGCGG-
3' 
593 bp 
blaOXA 
oxaF 5'-ACACAATACATATCAACTTCGC-3' 
oxaR 5'-AGTGTGTTTAGAATGGTGATC-3' 
813 bp 
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Table 2. 3: PCR reagents concentrations and quantities for ESBL multiplex PCR 
Reagent Final Concentration Quantity/reaction (µl) 
5X PCR reaction buffer 5X 5.0 
20mM dNTPs 0.2mM 0.25 
25mM MgCl2 2.5 mM 2.5 
5 U/µM Taq DNA polymerase 1.25 U/µM 0.25 
Sterile dH2O  11 
2.5 pmol Forward Primer 0.2 pmol 2.0 
2.5 pmol Reverse Primer 0.2 pmol 2.0 
DNA ~3 ng/ µl 2.0 
Total  25 
 
 
Table 2. 4: PCR conditions for ESBL multiplex PCR 
Step Temperature Time  
Preheat lid 95ºC 1 min 
Initial denaturation 94ºC 5 min 
30 cycles of steps 1,2,3 
1) Denaturation 94ºC 30 sec 
2) Annealing 62ºC 90 sec 
3) Elongation 72ºC 60 sec 
Final elongation 72ºC 10 min 
Final hold 10ºC ∞ 
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2.5 PCR detection of Virulence Associated Genes (VAGs) carriage 
E. coli isolates from the clinical samples of bacteraemia and UTIs were screened for the 
presence of VAGs by multiplex PCR with reference to a previously published protocol 
(Johnson and Stell, 2000). The protocol describes thirty different VAGs associated with 
pathogenicity islands, adhesins, toxins and others that are divided in 5 multiplex PCR pools. 
Primer sequences, PCR reagent concentrations and PCR conditions are described in Table 2.5, 
Table 2.6 and Table 2.7 respectively. PCR products were run on a 2% agarose gel and VAGs 
carriage was determined for each isolate. 
 
 
Table 2. 5: VAGs multiplex PCR primer sequences and PCR product sizes  
Gene/function 
Primer 
Name 
Primer sequence  size (bp) 
adhesins 
papAH 
PapA f 
PapA r 
5'-ATGGCAGTGGTGTCTTTTGGTG-3' 
5'-CGTCCCACCATACGTGCTCTTC-3' 
720 
papC 
PapC f 
PapC r 
5'-GTGGCAGTATGAGTAATGACCGTTA-3' 
5'-ATATCCTTTCTGCAGGGATGCAATA-3' 
200 
papEF 
PapEF f 
PapEF r 
5'-GCAACAGCAACGCTGGTTGCATCAT-3' 
5'-AGAGAGAGCCACTCTTATACGGACA-3' 
336 
papG 
II, III 
I(flanking region) 
pGf 
pGr 
pG1"r 
5'-CTGTAATTACGGAAGTGATTTCTG-3' 
5'-ACTATCCGGCTCCGGATAAACCAT-3' 
5'-TCCAGAAATAGCTCATGTAACCCG-3' 
1070 
 
1190 
allele I 
AlleleI-f 
AlleleI-r 
5'-TCGTGCTCAGGTCCGGAATTT-3' 
5'-TGGCATCCCCCAACATTATCG-3' 
461 
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allele I' 
AlleleI'-f 
AlleleI'-r 
5'-CTACTATAGTTCATGCTCAGGTC-3' 
5'-CTGACATCCTCCAACATTATCGA-3' 
474 
allele II 
AlleleII-f 
AlleleII-r 
5'-GGGATGAGCGGGCCTTTGAT-3' 
5'-CGGGCCCCCAAGTAACTCG-3' 
190 
allele III 
AlleleIII-f 
AlleleIII-r 
5'-GGCCTGCAATGGATTTACCTGG-3' 
5'-CCACCAAATGACCATGCCAGAC-3' 
258 
sfa/focDE 
sfa1 
sfa2 
5'-CTCCGGAGAACTGGGTGCATCTTAC-3' 
5'-CGGAGGAGTAATTACAAACCTGGCA-3' 
410 
sfaS 
SfaS f 
SfaS r 
5'-GTGGATACGACGATTACTGTG-3' 
5'-CCGCCAGCATTCCCTGTATTC-3' 
240 
focG 
FocG f 
FocG r 
5'-CAGCACAGGCAGTGGATACGA-3' 
5'-GAATGTCGCCTGCCCATTGCT-3' 
360 
afa/draBC 
Afa f 
Afa r 
5'-GGCAGAGGGCCGGCAACAGGC-3' 
5'-CCCGTAACGCGCCAGCATCTC-3' 
559 
bmaE 
bmaE-f 
bmaE-r 
5'-ATGGCGCTAACTTGCCATGCTG-3' 
5'-AGGGGGACATATAGCCCCCTTC-3' 
507 
gafD 
gafD-f 
gafD-r 
5'-TGTTGGACCGTCTCAGGGCTC-3' 
5'-CTCCCGGAACTCGCTGTTACT-3' 
952 
nfaE 
nfaE-f 
nfaE-r 
5'-GCTTACTGATTCTGGGATGGA-3' 
5'-CGGTGGCCGAGTCATATGCCA-3' 
559 
fimH 
FimH f 
FimH r 
5'-TGCAGAACGGATAAGCCGTGG-3' 
5'-GCAGTCACCTGCCCTCCGGTA-3' 
508 
Toxins 
hlyA 
hly f 
hly r 
5'-AACAAGGATAAGCACTGTTCTGGCT-3' 
5'-ACCATATAAGCGGTCATTCCCGTCA-3' 
1177 
cnf1 
cnf1 
cnf2 
5'-AAGATGGAGTTTCCTATGCAGGAG-3' 
5'-CATTCAGAGTCCTGCCCTCATTATT-3' 
498 
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cdtB 
cdt-a1 
cdt-a2 
cdt-s1 
cdt-s2 
5'-AAATCACCAAGAATCATCCAGTTA-3' 
5'-AAATCTCCTGCAATCATCCAGTTTA-3' 
5'-GAAAGTAAATGGAATATAAATGTCCG-3' 
5'-GAAAATAAATGGAACACACATGTCCG-3' 
430 
Siderophores 
fyuA 
FyuA f 
FyuA r 
5'-TGATTAACCCCGCGACGGGAA-3' 
5'-CGCAGTAGGCACGATGTTGTA-3' 
880 
iutA 
AerJ f 
AerJ r 
5'-GGCTGGACATCATGGGAACTGG-3' 
5'-CGTCGGGAACGGGTAGAATCG-3' 
300 
Polysaccharide coatings 
kpsMT II 
kpsII f 
kpsII r 
5'-GCGCATTTGCTGATACTGTTG-3' 
5'-CATCCAGACGATAAGCATGAGCA-3' 
272 
kpsMT III 
KpsIII f 
KpsIII r 
5'-TCCTCTTGCTACTATTCCCCCT-3' 
5'-AGGCGTATCCATCCCTCCTAAC-3' 
392 
kpsMT K1 K1-f 
K5-f 
5'-TAGCAAACGTTCTATTGGTGC-3' 
5'-CAGTATCAGCAATCGTTCTGTA-3' 
153 
kpsMT K5 159 
Miscellaneous 
rfc 
rfc-f 
rfc-r 
5'-ATCCATCAGGAGGGGACTGGA-3' 
5'-AACCATACCAACCAATGCGAG-3' 
788 
ibeA 
ibe10 f 
ibe10 r 
5'-AGGCAGGTGTGCGCCGCGTAC-3' 
5'-TGGTGCTCCGGCAAACCATGC-3' 
170 
cvaC 
ColV-Cf 
ColV-Cr 
5'-CACACACAAACGGGAGCTGTT-3' 
5'-CTTCCCGCAGCATAGTTCCAT-3' 
680 
traT 
TraT f 
TraT r 
5'-GGTGTGGTGCGATGAGCACAG-3' 
5'-CACGGTTCAGCCATCCCTGAG-3' 
290 
PAI 
RPAi f 
RPAi r 
5'-GGACATCCTGTTACAGCGCGCA-3' 
5'-TCGCCACCAATCACAGCCGAAC-3' 
930 
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Table 2. 6: PCR reagents concentrations for each pool of VAGs multiplex PCR. 
Multiplex primer 
Pools 
Reagent Final Concentration 
Quantity per 
reaction (µl) 
 
 
Pool 1 
 
PAI, papA, fimH, kps 
MT III, papEF and 
ibeA. 
 
 
5X PCR reaction buffer 5X 5.0 
20mM dNTPs 0.8mM 1.0 
25mM MgCl2 4 mM 4.0 
5 U/µM Taq DNA polymerase 2.5 U/µM 0.5 
Sterile dH2O  6.5 
30 µM Forward Primer 600 pmol 0.5 
30 µM Reverse Primer 600 pmol 0.5 
DNA Template ~3 ng/ µl 2.0 
Total 25 
Pool 2 
fyuA, bmaE, sfa/foc, 
iutA, papG allele III 
and K1 (KpsIIr with 
K1-f) 
5X PCR reaction buffer 5X 5.0 
20mM dNTPs 0.8mM 1.0 
25mM MgCl2 4 mM 4.0 
5 U/µM Taq DNA polymerase 2.5 U/µM 0.5 
Sterile dH2O  6.5 
30 µM each Forward Primer 600 pmol 0.5 
30 µM each Reverse Primer 600 pmol 0.5 
DNA Template ~3 ng/ µl 2.0 
Total 25 
Pool 3 
 
hlyA, rfc, 
*nfaE,*papG allele I 
(internal), *kps MT II 
and *papC 
* require 10µM 
concentration 
5X PCR reaction buffer 5X 5.0 
20mM dNTPs 0.8mM 1.0 
25mM MgCl2 4 mM 4.0 
5 U/µM Taq DNA polymerase 2.5 U/µM 0.5 
Sterile dH2O  8.5 
30 µM each Forward Primer 600 pmol 0.5 
30 µM each Reverse Primer 600 pmol 0.5 
*30 µM Forward Primer 300 pmol 0.25 
*30 µM  Reverse Primer 300 pmol 0.25 
DNA Template ~3 ng/ µl 2.0 
Total 25 
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Pool 4  
gafD, cvaC, cdtB, 
focG, traT and papG 
allele II 
 
5X PCR reaction buffer 5X 5.0 
20mM dNTPs 0.8mM 1.0 
25mM MgCl2 4 mM 4.0 
5 U/µM Taq DNA polymerase 2.5 U/µM 0.5 
Sterile dH2O  6.5 
30 µM Forward Primer 600 pmol 0.5 
30 µM Reverse Primer 600 pmol 0.5 
DNA Template ~3 ng/ µl 2.0 
Total 25 
Pool 5 
papG allele I 
(flanking), papG 
allele II (flanking), 
papG allele III 
(flanking), 
*afa/draBC, 
*cnf1,*sfaS and K5 
(KpsIIr with K5-f) 
* require 10µM 
concentration 
5X PCR reaction buffer 5X 5.0 
20mM dNTPs 0.8mM 1.0 
25mM MgCl2 4 mM 4.0 
5 U/µM Taq DNA polymerase 2.5 U/µM 0.5 
Sterile dH2O  9 
30 µM each Forward Primer 600 pmol 0.5 
30 µM each Reverse Primer 600 pmol 0.5 
*30 µM Forward Primer 300 pmol 0.25 
*30 µM  Reverse Primer 300 pmol 0.25 
DNA Template ~3 ng/ µl 2.0 
Total 25 
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Table 2. 7: PCR reaction conditions for VAGs multiplex PCR 
Step Temperature Time  
Preheat lid 95ºC 1 min 
Initial denaturation 95ºC 5 min 
25 cycles of steps 1,2,3 
1) Denaturation 94ºC 30 sec 
2) Annealing 63ºC 30 sec 
3) Elongation 68ºC 3 min 
Final elongation 72ºC 10 min 
Final hold 10ºC ∞ 
 
 
2.6 Multilocus Sequence Typing (MLST) 
DNA extractions of overnight LB broth cultures for each of the isolates from clinical samples 
of bacteraemia and UTI were obtained by using GenElute™ Bacterial Genomic DNA Kits 
(Sigma-Aldrich) to be used as template. PCR was performed to amplify the target seven 
housekeeping genes (adk, icd, fumC, purA, mdh, gyrB and recA) with reference to the Achtman 
scheme (mlst.ucc.ie). Primer sequences of each of the target genes, their PCR product size and 
annealing temperatures are described in Table 2.8. Tables 2.9 and 2.10 describe the PCR 
reagent concentrations and the PCR conditions respectively. All the PCR products were run on 
1% agarose gel for visualization. 
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Table 2. 8: PCR primer sequences, annealing temperatures (TM) and PCR product size 
for MLST 
Gene Forward and reverse primer names and sequences Product size TM 
adk 
adkF 5'-ATTCTGCTTGGCGCTCCGGG-3'  
adkR 5'-CCGTCAACTTTCGCGTATTT-3' 
583 bp 54° C 
fumC 
fumCF 5'-TCACAGGTCGCCAGCGCTTC-3'  
fumCR 5'-GTACGCAGCGAAAAAGATTC-3' 
806 bp 54° C 
gyrB 
gyrBF 5'-TCGGCGACACGGATGACGGC-3'  
gyrBR 5'-ATCAGGCCTTCACGCGCATC-3' 
911 bp 60° C 
icd 
icdF 5'-ATGGAAAGTAAAGTAGTTGTTCCGGCACA-3'  
icdR 5'-GGACGCAGCAGGATCTGTT-3' 
878 bp 54° C 
mdh 
mdhF 5'-ATGAAAGTCGCAGTCCTCGGCGCTGCTGGCGG-3'  
mdhR 5'-
TTAACGAACTCCTGCCCCAGAGCGATATCTTTCTT-3' 
932 bp 60° C 
purA 
purAF 5'-CGCGCTGATGAAAGAGATGA-3' 
purAR 5'-CATACGGTAAGCCACGCAGA-3' 
816 bp 54° C 
recA 
recAF 5'-CGCATTCGCTTTACCCTGACC-3'  
recAR 5'-TCGTCGAAATCTACGGACCGGA-3' 
780 bp 58° C 
 
 
Table 2. 9: PCR reagent concentrations and quantities for MLST 
Reagent Final Concentration Quantity/reaction (µl) 
5X PCR reaction buffer 5X 6.0 
10mM dNTPs 0.2mM 0.6 
50mM MgCl2 1.67 mM 1.0 
5 U/µM Taq DNA polymerase 0.03 U/µM 0.2 
Sterile dH2O  19.2 
10 pmol Forward Primer 1.67 pmol 0.5 
10 pmol Reverse Primer 1.67 pmol 0.5 
DNA ~3 ng/ µl 2.0 
Total 30 
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Table 2. 10: PCR reaction conditions for MLST 
Step Temperature Time  
Preheat lid 95ºC 1 min 
Initial denaturation 95ºC 10 min 
30 cycles of steps 1,2,3 
1) Denaturation 95ºC 30 sec 
2) Annealing Primer specific 30 sec 
3) Elongation 72ºC 30 sec 
Final elongation 72ºC 10 min 
Final hold 10ºC ∞ 
 
 
2.6.1 MLST PCR products cleanup 
All the MLST PCR products were prepared for sequencing by using Exo-SAP cleanup kit 
(affymetrix company item: 78201). A volume of 2µl of the Exo-SAP enzyme were added to 
5µl of PCR product in 96 wells plate which was sealed and placed in the thermal cycler. The 
thermal cycler was set to 15 minutes at 37ºC followed by 15 minutes at 80 ºC and 4ºC final 
hold. 
 
2.6.2 Sequencing of MLST PCR products 
All the MLST PCR products were Sanger sequenced by Source Bioscience LifeSciences. The 
MLST PCR products were sent in 96 wells plates prepared in the required concentrations of 
1ng/µl for PCR products and 3.2pmol/µl of primers. The volume required per read was of 15µl 
of each PCR product. 
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2.6.3 Analysis of MLST sequence data and determination of the sequence types 
(ST) 
All the raw sequence data received from Source Bioscience LifeSciences as processed using 
the software CLC Sequence Viewer (version 6.5.3). Forward and reverse sequences were 
imported for each gene. The reverse sequence was reverse complemented and aligned to its 
forward sequence. Any nucleotide differences between the two DNA strands were corrected 
by referring to the original chromatogram file using GENtle software. Bad sequence files were 
discarded and a new MLST PCR reaction was prepared and sent for sequencing. The consensus 
sequence resulting from the alignment for each MLST target gene for each isolate was obtained. 
The consensus sequence for each of the MLST target genes was submitted to the Achtman 
MLST scheme website (www.mlst.warwick.ac.uk/mlst/mlst/dbs/Ecoli) and their allelic 
numbers were obtained. The combination of all the allelic numbers of  the seven target genes 
was then submitted to the website for each isolate and their sequence type was determined. 
 
2.6.4 Generation of Minimum Spanning Trees (MSTs) 
Phyloviz 1.0 software was used to create minimum spanning trees for the E.coli populations 
from bacteraemia and UTI using non-concatenated sequences of the STs produced by MLST. 
The software utilizes the goeBURST algorithm to produce a complete minimum spanning tree 
clustering isolates depending on the level of similarities and differences in their ST allelic 
profiles (Francisco et al., 2012). 
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2.7 Serum resistance assay 
All twenty-two sequenced ST73 E.coli strains were tested for their response to the bactericidal 
effect of human serum. The procedure was adapted from the published protocol (Podchun et 
al., 2001). Initial bacterial suspensions were diluted to 2 X 106 in saline, then 250µl of from 
each suspension was added to 750µl of human serum in 24 well plates, mixed well and 
incubated at 37ºC for 3 hours. Viable counts were determined for each strain on LB agar by 
Miles and Misra method for both the initial inoculum (T0) and after three hours incubation in 
normal human serum (T3) and compared. Strains were recorded as resistant when they 
maintained or increased their viable counts compared to their initial counts (T0). Strains with 
decreased viable counts at (T3) to less than 50% of their initial count (T0) were recorded 
sensitive. E. coli MG1655 was used as serum sensitive control strain as they are cleared 
completely after incubation in normal human serum. E. coli CFT073 was used as a serum 
resistant control strain (Miajlovic et al., 2014). 
 
2.8 Genome sequencing of ST73 E. coli isolates 
A selection of ST73 E.coli isolates (n= 22) were cultured overnight in LB broth and DNA 
extraction was performed using GenElute™ Bacteria Genomic DNA Kits (Sigma-Aldrich). 
The DNA samples were sent for sequencing at Exeter Sequencing Service at the University of 
Exeter (Ess-wiki.exeter.ac.uk, 2014). The sequencing system Illumina HiSeq 2500 was used 
and 100bp paired end sequencing was performed (Systems.illumina.com, 2014).  
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2.9 Sequence assembly using Velvet and PAGIT 
All the raw sequence data were received from Exeter Sequencing Service in FASTQ file format. 
FASTQ files are text files that include the sequencing reads of the nucleotides and their 
associated quality scores (Cock, et al., 2010). Velvet software was used to assemble the 
sequences (Zerbino and Birney, 2008). Velvet is a de Bruijn graph assembler used for the 
production of de novo assembled genomes, which means it assembles the genomes without the 
use of a reference genome of a closely related strain (Swain, et al., 2012). Velvet assembly 
parameters were k-mer size of 31, expected coverage of 75-fold and coverage cutoff of 8 fold. 
Assembled genome sequences were used in the post assembly genome improvement toolkit 
(PAGIT). PAGIT software produces improved quality sequence from de novo assembled 
genomes by utilizing ABACAS, IMAGE, iCORN and RATT and a closely related reference 
strain (Swain, et al., 2012). In the PAGIT assembly CFT073 E. coli genome sequence (NCBI 
Reference Sequence: NC_004431.1, genome size is 5231428 bps) was used as a reference 
genome because it belonged to sequence type ST73. Full details of command lines and 
parameters are provided in the appendix (chapter six). 
 
2.10 Genome annotation  
Prokka is a rapid accurate unguided annotation tool compared to other transfer annotation 
softwares that produce errors as they force the transfer of annotations (Seemann, 2014). Only 
FASTA files of the assembled genomes are required to start the Prokka script where it utilizes 
a built in database to annotate the genome and produces output files in GFF and GENBANK 
(GBK) formats which are compatible annotation formats ready for further analysis (Seemann, 
2014). All the selected twenty two ST73 E. coli isolate genomes were annotated by using 
Prokka software. Command lines are provided in the appendix (chapter six).                    
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2.11 High resolution SNP typing and phylogeny 
 
2.11.1 Alignment of sequenced genomes 
The raw FASTQ sequence files of all sequenced ST73 E. coli isolates were aligned against E. 
coli CFT073 as a reference genome using SMALT software, which is developed and optimized 
by the Wellcome Trust Sanger Institute (Sanger.ac.uk, 2014). SMALT provides a more 
accurate alignment of paired end sequencing reads produced by Illumina, Roche 454 or ABI 
Sanger compared to other alignment programmes such as BWA and BOWTIE (Wellcome 
Trust Sanger Institute, 2014a). The SMALT alignment process involves first forming an index 
table of the reference genome consisting of specific length words or hashing with equidistant 
spaces, then sequence reads are mapped against the hash index (Wellcome Trust Sanger 
Institute, 2014b). SAMtools was used to extract the required information from SAM files 
generated by SMALT in the previous step. SAMtools software used to manipulate the data in 
SAM format files such as indexing, merging, sorting and other post processing requirements 
(Li et al., 2009; Evolution and Genomics, 2011). This results in VCF files containing all the 
SNP data for each strain against the reference genome E. coli CFT073. In house scripts were 
used by Alan McNally at NTU to filter and produce high fidelity SNPs. The filtering criteria 
for obtaining high fidelity SNPs for a phylogenetic tree was removing multiple alleles, 
removing reads with quality scores of less than thirty, removing SNPs reads with depth of 
coverage less than eight and with allele frequency of less than 75%. Full parameters and scripts 
are provided in the appendix (chapter six). 
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2.11.2 Construction of a phylogenetic tree 
The VCF files were used to create a consensus sequence for each strain based on the CFT073 
reference. RAxML-HPC was used to produce a maximum-likelihood phylogenetic tree with 
rapid bootstrapping and the (GTR) or general time reversible model with gamma distribution 
(Felsenstein, 1981; Rodriguez et al., 1990). The resulting phylogenetic tree was viewed using 
Figtree software (tree.bio.ed.ac.uk/software, 2014). More details and scripts are provided in the 
appendix (chapter six). 
 
2.11.3 Measurement of pairwise distance 
The FASTA files generated in section 4.2.7.3 were used to compute the number of base 
differences between the ST73 E coli strains using MEGA software (Tamura et al., 2013). A 
table was generated and exported as spreadsheet file for further analysis.  
 
2.12 Comparative Genome analysis 
Whole genome comparisons were performed using the software Gegenees (Gegenees.org, 
2014). Gegenees software allows the comparative analysis of hundreds of complete or draft 
genomes by aligning fragments of all the genomes utilizing a multithreaded BLAST approach. 
The alignment data can provide a phylogenetic view of the genomes, but more importantly for 
our study, it can be used to investigate the presence of genomic regions unique to a target group 
when compared to a background group (Agren et al., 2012). Gegenees software was also used 
to determine core and pangenome statistics. 
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2.12.1 Investigation of bacteraemia and ESBL carrier specific loci 
Gegenees software was used to investigate the presence or absence of genomic regions or loci 
specific only to bacteraemic or to ESBL carrier strains of the sequenced ST73 E. coli. This was 
performed by utilizing the Fragmented all-all comparison option (Gegenees.org, 2014). First, 
all twenty two GENBANK (GBK) files were imported into a new database in Gegenees. Then, 
in the Fragmented all-all comparison window, nucleotide comparison (BLASTN) was chosen 
with the highest resolution parameters for the alignment (200/100), which were 200 bps of 
sliding fragment window size and 100bps of progressive step size respectively. When the 
alignments and fragments comparison were performed and displayed, the bacteraemia strains 
were selected as target group against a background group of all the UTI strains in order to 
investigate for the presence of bacteraemia specific genomic regions or loci. The strain B134 
was chosen as reference genome from the target group to refer the unique loci to with 
annotations. In the other test, all the ESBL carrier strains were selected as a target group from 
bacteraemia and UTI clinical samples against a background group of ESBL absent strains in 
order to investigate ESBL carrier specific genomic regions, or loci with B134 strain as a 
reference from the target group.       
 
2.12.2 Determination of core and pangenome 
An overview of the core and pangenome of all the sequenced ST73 E. coli strains was created 
by Gegenees software. All the genomes were fragmented then compared to each other and their 
BLASTN scores were determined. The pangenome was constructed progressively by analysing 
the fragments BLASTN scores and then each new unique fragment was deposited in the 
pangenome (Gegenees.org, 2014). In the New pangenome option, 1% threshold was selected 
for maximum distinctive selection of unique fragments. 
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2.13 Plasmid profiling by S1 nuclease Pulsed Field Gel Electrophoresis (S1 
PFGE) 
The protocol of S1 nuclease treatment of genomic DNA for profiling plasmids was adapted 
from the published protocol of Barton et al., (1995). S1 PFGE is an established method used 
to detect, size and isolate plasmid DNA from bacteria (Keyes et al., 2000; Basta et al., 2004; 
Zong et al., 2010; Brolund et al., 2013). S1 nuclease is an endonuclease enzyme isolated from 
Aspergillus oryzae that cleaves single stranded nucleic acids. It can also degrade double 
stranded DNA in specific regions where single stranded DNA is exposed by a nick, a mismatch, 
a gap or a loop (Lehman, 1981). In case of supercoiled plasmids torsional stress occurs in the 
molecule that becomes sensitive to S1 nuclease activity. Once one strand is cleaved, S1 
nuclease cuts the intact strand at the nick opposite to the initial break (Barton et al., 1995). The 
S1 nuclease is known to cut double stranded genomic DNA, but much less frequently. 
Subsequently, linearized plasmids are isolated and separated by PFGE as bands in a faint smear 
of genomic DNA background. The size of the plasmid is accurately determined with reference 
to DNA markers (Barton et al., 1995). All thirteen ESBL carrier strains (B10, B18, B29, B36, 
B40, B72, B73, B84, B91, B134, U42, U50 and U76) were selected and three CTX-M negative 
strains (B14, B102 and U24) were selected (Table 4.1A and Table 4.1B). NCTC13353 E. coli 
was used as a positive control for a plasmid carrier.      
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2.13.1 Reagents and Buffers 
1 M Tris-HCL ( pH 8.0) 
A final concentration of 1 M Tris-HCL was obtained by dissolving 121.1 g of Tris base (Fisher 
Scientific) in 700 ml of dH2O at 56°C with magnetic steering. Concentrated HCL and ultra-
pure water was added gradually maintaining pH of 8.0 to complete 1 L. The reagent was 
autoclaved and stored at room temperature. 
 
0.5 M EDTA (pH 8.0) 
A final concentration of 0.5 M ethylenediamine tetra-acetic acid, sodium hydroxide (EDTA) 
buffer was prepared by dissolving 186.1 g of EDTA (Sigma Aldrich) in 700 ml of dH2O with 
the addition of Sodium hydroxide (NaOH) to adjust the pH to 8.0, the solution was then made 
up to 1 L by adding de-ionized water. The reagent was autoclaved and stored at room 
temperature. 
 
10 X TBE Buffer 
A final concentration of 10 X Tris base, boric acid and EDTA (TBE) buffer was obtained by 
dissolving 108 g Tris base and 55 g boric acid (Fisher Scientific) in 700 ml of  dH2O. Then, 80 
ml of 0.5 M EDTA (pH 8.0) was added and the mixture was completed to 1 L by adding dH2O. 
 
Tris:EDTA (TE) buffer 
The final concentration of TE buffer was 10 mM Tris-HCL:1 mM EDTA, pH 8.0. It was 
prepared by adding 10 ml of 1 M Tris-HCL (pH 8.0) to 2 ml of 0.5 M EDTA (pH 8.0). 
  
52 
 
 
Cell Suspension Buffer (CSB) 
The final concentration of CSB was 100 mM Tris-HCl:100 mM EDTA, pH 8.0. It was prepared 
by adding 10 ml of 1 M Tris-HCl (pH 8.0) to 20 ml of 0.5 M EDTA (pH 8.0). Sterile pure 
water was used to complete the buffer to 1 L. 
 
Cell Lysis Buffer (CLB) 
CLB was prepared by mixing 25 ml of 1 M Tris-HCl (pH 8.0) with 50 ml of 0.5 M EDTA (pH 
8.0). Then 50 ml of 10% Sarcosyl (N-Lauroyl-Sarcosine Sodium salt, Sigma Aldrich) was 
added and the mixture was diluted by sterile pure water to 500 ml. Just before use, 25μl 
Proteinase K (20 mg/ml, Sigma Aldrich) was added to every 5 ml of CLB. The final 
concentration of CLB was 50 mM Tris-HCl:50 mM EDTA, pH 8.0, 1% Sarcosyl and 0.1 mg/ml 
Proteinase K. 
 
DNA Markers and other products 
Other reagents and DNA markers were used in the S1 PFGE as follows: MidRange I PFGE 
Marker (New England Biolabs), Low Range PFGE Marker (New England Biolabs), S1 
Nuclease (Promega), SeaKem® Gold Agarose (Biozym Diagnostics),  N-Lauroylsarcosine 
sodium salt (Sigma Aldrich), Lysozyme from chicken egg white (Sigma Aldrich), Thiourea 
(Sigma Aldrich) and Proteinase K (Sigma Aldrich). 
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2.13.2 S1 PFGE protocol 
Bacterial cultures 
E. coli cultures were incubated for overnight at 37°C on LB agar. 
 
Preparation of the agar plugs with the bacteria 
0.1g of SeaKem® Gold Agarose (Biozym Diagnostics) was dissolved in 9.5 ml TE and 500 µl 
of 20% sodium dodecyl sulphate (SDS) and kept in a water bath at 55℃. Working on ice, two 
or three loops of bacterial colonies were suspended in 1.6ml of Cell Suspension Buffer (CSB) 
and Centrifuged at 7000rpm for 4 min. The supernatant was discarded and the pellet was 
washed again with another 1.6ml CSB. Centrifugation was repeated and the cells were 
resuspended in 1ml of CSB. The optical density (OD) of the bacteria suspension was adjusted 
to 1.4 at wave length of 600 nm. In a 1.5 ml Eppendorf, 400 µl of the bacterial suspension was 
transferred and incubated at 37℃ for 10 min in water bath. After the incubation, 25µl of 
proteinase K (20mg/ml) was added and mixed gently by tapping them 3 to 4 times. Then, 400µl 
of agarose was added and gently mixed using non sharp tips. Finally, the mixture was added 
into the plug moulds carefully to avoid the formation of bubbles and the moulds were incubated 
at 4℃ for 10 min.  
 
Bacterial Cell Lysis 
Cell lysis buffer (CLB) was prepared for bacterial cell lysis. For every 5ml of CLB, 25µl of 
proteinase K (20mg/ml) and 0.5mg lysozyme (Sigma Aldrich) were added and mixed 
thoroughly. Then, each of the prepared plugs earlier were transferred into 2 ml of the prepared 
CLB ensuring that they were completely immersed in the buffer and incubated in a water bath 
at 55℃ for 2 hours.  
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Washing the plugs after the bacterial cell lysis 
Ultra-pure water and TE buffer were equilibrated in a water bath at 55℃ before use. The 
plugs were transferred to 2 ml Eppendorf tubes filled with ultra-pure water and washed by 
pipetting. Then the plugs were transferred to a 15 ml Falcon tube filled with ultra-pure water 
and incubated at 50℃ in a water bath with shaking for 15 min. The washing was repeated 
once with ultra-pure water and repeated all again three times with TE buffer. After discarding 
the liquid of the final wash, 10 ml of TE buffer (stored at room temperature) was added to the 
plugs which were then stored at 4℃. 
 
Digestion with S1 nuclease 
The plugs were transferred to a new Eppendorf tube containing 200 μl of 1X S1 nuclease buffer 
(10 X, Promega) and incubated for 20 min at room temperature. Then, the buffer was discarded 
and 100 μl of fresh buffer with 0.2μl of nuclease S1 (89 U/μl, Promega) was added, and the 
tube was incubated for 45 min at 37°C. The reaction was stopped by adding 10 μl of 0.5 M 
EDTA (pH 8) and left for 30min at room temperature. Finally, 1ml of 1 X TE buffer was added 
to the Eppendorf with the plugs and left at 4°C for 30 min.  
 
Electrophoresis 
A concentration of 200 uM Thiourea (Sigma Aldrich) in 0.5 X TBE buffer was prepared by 
dissolving 15.22mg for 1L of 0.5 X TBE, a total of 2500 ml of 0.5 X TBE was used for a single 
electrophoresis run. The agar was prepared by dissolving 1g of SeaKem® Gold Agarose 
(Biozym Diagnostics) in 100ml mixture of TBE and Thiourea by incubation in a water bath at 
55℃. The plugs and DNA Markers were placed on the comb and dried with a filter paper then 
the comb was fitted in the electrophoresis tray. The gel was then poured and kept for 30 min at 
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room temperature to solidify. The comb was removed and the wells were filled with liquid gel. 
Finally, the gel was placed in the tank and electrophoresis was run on the conditions: Block 1, 
6V/cm, initial switch 5s, final switch 40s, run time 12h; Block 2, 6V/cm, initial switch 3s, final 
switch 8s, run time 8h. The gel was stained with Ethidium Bromide (1µg/ml) for 30 min and 
photographed. 
 
2.14 Plasmid typing by Plasmid Finder database 
Plasmid finder is a web based tool developed to identify the presence of plasmids and determine 
their replicon types from whole or partial, raw or sequenced genome and plasmid sequences of 
bacteria belonging to the Enterobacteriaceae family (Carattoli et al., 2014). The database was 
constructed from 559 sequenced plasmids collected from the database of the National Centre 
for Biotechnology (NCBI) to produce a plasmid replicon sequence identification tool through 
the openly accessed website (www.cge.cbs.dtu.dk). FASTA files of all the thirteen ESBL 
positive ST73 E. coli strains from the clinical samples of bacteraemia and UTI were used with 
the assembled input files option on the website. Gram negative Enterobacteriaceae with 80% 
threshold option were selected and the output was obtained. 
 
2.15 Statistical analysis 
SPSS software (version 19.0) was used to perform the statistical analysis of the data. Chi square 
test was used to determine statistical differences of the antibiotic resistance profiles, ESBL 
carriage, VAGs presence and ST prevalence between bacteraemia and UTI E.coli isolates. The 
normal distribution was confirmed and an independent t test was performed to test statistical 
differences in VAGs carriage of E.coli isolates from bacteraemia and UTI. 
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Chapter three 
Comparison of E. coli populations from clinical samples of UTI 
and bacteraemia 
 
 
 
 
 
 
 
 
 
57 
 
3.1 Introduction 
 
3.1.1 Population studies of E. coli 
Numerous population studies of E. coli have been performed due its importance as a human 
pathogen (Hartl and Dykhuizen, 1984). Population studies have been performed to investigate 
the epidemiology of the emerging ESBL producing E. coli phenotypes to define their incidence 
and risk factors (Pitout, et al., 2004). The development of molecular techniques such as multi 
locus enzyme electrophoresis (MLEE) was the basis of many population genetic studies and 
established the link between virulence and phylogenetic groups (Clermont, et al., 2000; 
Johnson and Russo, 2002). Based on MLEE all E. coli strains can be divided into 4 main 
phylogenetic groups namely A, B1, B2 and D. Commensal E. coli strains are found in 
phylogenetic groups A or B1. E. coli strains which cause intestinal disease are found in A, B1 
or D groups, while ExPEC strains in general are found in group B2, or to a lesser extent in 
group D (Jaureguy, et al., 2008).  
Genotyping methods are being increasingly used to characterize bacterial pathogens in 
population genetics studies. Multi-locus sequence typing (MLST) is considered the main 
genotyping tool for identifying different strains of ExPEC (Tartof, et al., 2005). MLST 
identifies specific sequences within seven housekeeping genes that are conserved throughout 
the species. Each gene is given an allelic number and the combination of the seven allelic 
numbers produces a unique sequence type (ST) associated with the strain. The Achtman 
scheme is the main established MLST typing scheme for E. coli (Wirth et al., 2006). MLST 
played a major role in identifying the global emergence of the pandemic ST131 E. coli clone 
(Nicolas-Chanoine, et al., 2008). Many MLST based population studies have since been 
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performed and confirmed the clonality of ST131 E. coli which is highly associated with CTX-
M-15 ESBL mediated antimicrobial resistance (Nicolas-Chanoine, et al., 2008).  
The structure of the E. coli UTI population in the East Midlands area was previously 
investigated by our group (Croxall et al., 2011). One hundred and fifty random UTI E. coli 
isolates were collected and characterized in terms of MLST, antibiotic sensitivity, VAGs 
acquisition and in vitro invasion of epithelial cells. That study reported that E.coli isolated from 
UTI infections were resistant to front line antibiotics with increased resistance to ciprofloxacin 
and trimethoprim. The genotypic structure of the UTI population revealed a diverse population 
consisting of a total of 52 STs. ST131 complex represented the most dominant ST accounting 
for 22% of the population, followed by ST73 (11%) and ST69 (9%). Whole genome 
comparisons revealed that the dominant ST131 isolates were genetically homogeneous with 
between 10 and 60 SNPs difference between circulating UTI isolates in the region (Clark et al., 
2012).    
 
3.1.2 Aim 
The population structure of UTI E. coli isolates is well characterized in the literature. Our group 
have contributed to defining the UTI E. coli population in the East Midlands area where a 
diverse population was observed consisting of 52 STs, only 26% of which were multi drug 
resistant ESBL carriers primarily represented by ST131 isolates while the remaining majority 
of STs were drug susceptible (Croxall, et al., 2011). Incidence of bacteraemia due to E. coli is 
increasingly reported worldwide. More importantly, bacteraemia due to multidrug resistant 
ESBL positive E. coli is also on the increase. Yet the population structure of E. coli causing 
bacteraemia is poorly defined. It would be beneficial to perform a thorough investigation of 
the molecular epidemiology of E. coli causing bacteraemia to determine if the UTI population 
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structure is mirrored in bloodstream infections. Clinical E. coli isolates from bacteraemia were 
collected from Nottingham University Hospital (NUH) with a contemporaneous collection of 
urine E. coli isolates from the period of March 2011 to July 2011, to contextualize our findings 
and provide a comprehensive snapshot of the epidemiology of the circulating ExPEC in the 
region. Specific aims of this chapter are: 
A) Phenotypic characterization of E. coli isolates from clinical samples of bacteraemia and 
UTI in terms of antibiotic susceptibility profiles, ESBL carriage and VAGs carriage. 
B) Genotypic characterization of the population structure of E. coli populations from 
bacteraemia and UTI by MLST. 
C) Comparison between the E. coli isolates from bacteraemia and UTI to provide a 
comprehensive view of the existing ExPEC genetic epidemiology in bacteraemia and UTI. 
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3.2 Results 
 
3.2.1 Increased levels of antibiotic resistance in clinical E. coli bacteraemia 
isolates compared to UTI isolates. 
140 E. coli isolates from clinical cases of bacteraemia and 125 E. coli isolates from clinical 
cases of UTI collected from Nottingham University Hospital were tested for their antibiotic 
susceptibility according to the BSAC protocol as displayed in Figure 3.1. 
 
Figure 3. 1: Disc diffusion antibiotic susceptibility test. The figure displays an image of the 
disc diffusion susceptibility test of two bacteraemia E. coli isolates B134 (top two iso-sensitest 
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agar plates) and B135 (bottom two iso-sensitest agar plates). We notice the difference between 
the resistance profile of the B134 strain to ampicillin and trimethoprim displayed by the 
absence of clear zones around the discs (top left) compared to B135 (bottom left). 
 
For all the antibiotics that were tested, the proportions of resistant bacteraemia E.coli isolates 
were higher than the UTI E. coli isolates (Figure 3.2). Differences in the percentages of 
resistance between the bacteraemia and UTI isolates were noticeable against ampicillin 
(63.6%/54.4%), ciprofloxacin (25.7%/8.8%) and cefradine (20%/11.2%), with statistical 
significant difference in resistance to ciprofloxacin (P≤0.001, 95% confidence interval is ±4.6) 
and cefradine (P≤0.05, 95% confidence interval is ±4.4).  
 
Figure 3. 2: Proportions of antibiotic susceptibility profiles of E. coli bacteraemia and 
UTI. The figure displays the percentages of bacteraemia and UTI E. coli isolates  resistance to 
front line antibiotics gentamicin (GM), ceftazidime (CAZ), meropenem (MEM), piperacillin-
tazobactam (PTZ), co-amoxiclav (AUG), trimethoprim (TM), ciprofloxacin (CIP), cefradine 
(CRD), nitrofurantoin (NI), and ampicillin (AP). Statistically significant differences in 
resistance to ciprofloxacin (P≤0.001) and cefradine (P≤0.05) are indicated. 
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The level of high antibiotic resistance of the bacteraemia E.coli isolates is further emphasized 
in Figure 3.3 which describes the number of isolates in the two populations displaying a 
multiple drug resistance (MDR) phenotype, exhibiting resistance to antibiotics belonging to 
two or more different groups of antibiotics. Our data shows a significantly higher number of 
MDR bacteraemia E. coli isolates than UTI E. coli isolates (P=0.01, 95% confidence interval 
is ±5.9). 
 
 
Figure 3. 3: Levels of multiple antibiotic drug resistance (MDR) in the clinical isolates. 
The figure shows the number of (MDR) phenotypes displayed by bacteraemia and UTI E. coli 
isolates. MDR phenotypes defined as exhibiting resistance to antibiotics belonging to two or 
more different classes of antibiotics. Data shows a significantly higher number of MDR 
bacteraemia E. coli isolates than UTI E. coli isolates (P=0.01). The graph also shows that the 
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phenotypic expression of ESBLs by the double disc sensitivity test was found to be 
significantly higher in bacteraemia E. coli isolates compared to UTI E. coli isolates (n=21/n=8, 
P=0.025, 95% confidence interval is ±3.9). 
 
3.2.2 Significantly higher ESBL carriage in bacteraemia E. coli isolates compared 
to UTI E. coli isolates 
PCR screening for ESBL carriage was performed on all E. coli isolates as displayed in Figure 
3.4. Compared to the UTI E. coli population, bacteraemia E. coli isolates presented 
significantly higher percentages of ESBL carriage for blaSHV (15.7%/5.6%, P=0.008, 95% 
confidence interval is ±3.7), blaCTX-M (29.3%/17.6%, P=0.025, 95% confidence interval is ±5.1) 
and blaOXA (14.3%/6.4%, P=0.037, 95% confidence interval is ±3.7) but not blaTEM 
(88.6%/84%, P=0.28, 95% confidence interval is ±4.1). In turn, the total ESBL carriage, 
excluding blaTEM, in the bacteraemia population was significantly higher than the UTI E. coli 
population (59.3%/29.6%, P≤0.001, 95% confidence interval is ±6). Production of ESBLs was 
tested against all the E. coli isolates from the two clinical groups of bacteraemia and UTI with 
the use of ESBL combination discs tests (Figure 3.3). Consistent with the results of ESBL PCR 
screening, phenotypic production of ESBLs was significantly higher among bacteraemia E. 
coli isolates than UTI E. coli isolates (n=21/n=8, p=0.025, 95% confidence interval is ±3.9). 
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Figure 3. 4: ESBL screening multiplex PCR gel image. The figure displays the gel image of 
ESBL multiplex PCR for SHV (237bp), TEM (445bp), CTXM (593bp) and OXA (813bp). 
Lanes 1-8 represent the samples B36, B40, B134, B72, B14, B47, B51, and B62 respectively. 
Positive controls for each of the ESBL primers were used which are NCTC 13351 E. coli (C1), 
NCTC 13353 E. coli (C2) and NCTC 13368 Klebsiella pneumoniae. Negative control 
contained no DNA template. 
 
Figure 3. 5: Percentages of ESBL carriage of the bacteraemia and UTI clinical isolates. 
The figure displays the percentages of ESBL carriage of bacteraemia and UTI isolates. 
Significant difference in carriage of ESBL determinants blaSHV (P=0.008), blaCTX-M (P=0.025) 
and blaOXA (P=0.037) but not blaTEM (P=0.28).  
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3.2.3 MLST shows a reduction in diversity in the bacteraemia population 
compared to the UTI population 
MLST sequence types were determined for all E. coli isolates using the Achtman scheme 
(Wirth et al., 2006). The UTI population was represented by 63 different STs with diverse 
prevalence. The highest ST prevalence in the UTI population was ST73 (n=16, 12.8%), 
followed by a gradual decrease in the prevalence of the other STs such as ST131 (n=9, 7.2%), 
ST69 (n=9, 7.2%), ST95 (n=6, 4.8%), ST404 (n=6, 4.8%), ST127 (n=4, 3.2%), ST141 (n=4, 
3.2%) and ST10 (n=3, 2.4%). Prevalence patterns of the STs of the bacteraemia E. coli 
population were noticeably different. Three main STs were obtained with ST131 being the 
most dominant (n=30, 21.4%) and significantly higher in prevalence than the UTI population 
(P≤0.001, 95% confidence interval is ±4.3), followed by ST73 (n=24, 17.1%) and ST95 (n=13, 
9.2%). There was a marked decrease in the prevalence of the other STs in the bacteraemia 
population such as ST69 (n=5, 3.6%), ST12 (n=4, 2.9%), ST2278 (n=3. 2.1%), ST10 (n=2, 
1.4%) and ST14 (n=2, 1.4%). Loss of diversity in the bacteraemia E. coli population was 
illustrated in Figure 3.6 as only eight of the most prevalent STs represent 59.2% of the total 
population, while the eight most prevalent STs in the UTI population represented only 45.6% 
of the total population. 
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Figure 3. 6 Prevalence Patterns of the major STs in UTI and bacteraemia populations. (A) The UTI population was represented by 63 
different STs with diverse prevalence, ST73 (n=16), ST131 (n=9), ST69 (n=9), ST95 (n=6), ST404 (n=6), ST127 (n=4), ST141 (n=4) and ST10 
(n=3). (B)  Prevalence patterns of the STs of the bacteraemia E. coli population were noticeably different. ST131 (n=30) is significantly higher in 
prevalence than the UTI population (P≤0.001), followed by ST73 (n=24), ST95 (n=13), ST69 (n=5), ST12 (n=4), ST2278 (n=3), ST10 (n=2) and 
ST14 (n=2). 
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3.2.4 Reduction in diversity of the bacteraemia population is associated with ESBL 
carriage 
Minimum spanning trees (MST) were created using the Phyloviz 1.0 software (Francisco, et 
al., 2012) to visualize the different STs of the two E. coli populations from bacteraemia and 
UTI in relation to each other according to similarities and differences in their MLST allelic 
profiles. In the MST (Figures 3.7 and 3.8), each circle represents one ST, and the size of the 
circle reflects the number of isolates belonging to this particular ST within the bacteria 
population. The lines between the circles represent how different their allelic profiles are, 
where a line labelled by number one means the two linked STs differ in at least one of the seven 
alleles which is named a single locus variant (SLV), and a cluster of STs linked by SLVs are 
referred to as a clonal complex (Francisco, et al., 2012). The UTI E. coli population MST 
(Figure 3.7) was found to be diverse with evenly distributed high prevalent STs, ST73 (n=16), 
ST131 (n=9), ST69 (n=9), ST95 (n=6) and ST404 (n=6). They are displayed in almost equal 
sizes and slightly larger than the remaining STs of the UTI population. In contrast, the loss of 
diversity of the bacteraemia E. coli population was more apparent in their MST (Figure 3.8) 
with the three dominant STs ST131 (n=30), ST73 (n=24) and ST95 (n=13) clearly larger than 
the other STs.   
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Figure 3. 7: Minimum Spanning Tree of UTI E. coli isolates. Each circle represents one ST, and the size of the circle reflects the number of 
isolates belonging to this particular ST within the bacteria population. The lines between the circles represent how different their allelic profiles 
are, where a line labelled by number one means the two linked STs differ in at least one of the seven alleles which is named a single locus variant 
(SLV), and a cluster of STs linked by SLVs are referred to as a clonal complex. Diversity of the UTI population is displayed with the main STs 
(ST73 n=16, ST131 n=9, ST69 n=9, ST95 n=6 and ST404 n=6) highlighted in different colours.  
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Figure 3. 8: Minimum spanning tree of bacteraemia E. coli isolates. Each circle represents one ST, and the size of the circle reflects the number 
of isolates belonging to this particular ST within the bacteria population. The lines between the circles represent how different their allelic profiles 
are, where a line labelled by number one means the two linked STs differ in at least one of the seven alleles which is named a single locus variant 
(SLV), and a cluster of STs linked by SLVs are referred to as a clonal complex. Loss of diversity of the bacteraemia population is displayed with 
the three dominant STs (ST131 n=30, ST73 n=26 and ST 95 n=16) highlighted in different colours.  
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The prevalence of ESBL genes was mapped onto the UTI and bacteraemia population MSTs 
(Figures 3.9 and 3.10). ESBL carriage in the UTI population was focussed on a small number 
of STs. Nineteen STs out of the total sixty three STs (30.1%) comprising the UTI population 
contained ESBL positive isolates (Fig 3.9). At the ST level, the aforementioned eight 
predominant STs within the UTI population exhibited differing levels of ESBL carriage, with 
the predominant ST73 group composed of 18.7% (n=3 of 16) of ESBL positive isolates. The 
remaining predominant STs of the UTI population exhibited ESBL positive isolates at the 
following levels: ST131 (44.4%, n=4 of 9), ST69 (33.3%, n=3 of 9), ST95 (50%, n=3 of 6), 
ST404 (0%), ST127 (0%), ST141 (0%) and ST10 (0%).  
In stark contrast, thirty STs out of the total fifty eight STs (51.7%) of the bacteraemia 
population contained ESBL positive isolates, which is significantly higher than the number of 
ESBL positive STs of the UTI population (51.7%/30.1%, p=.016, 95% confidence interval is 
±6, Figure 3.10). At the ST level there was variation in the proportions of ESBL positive 
isolates within the bacteraemia population compared to the UTI population amongst the 
predominant STs. Sequence types ST131 (50%, n=15 of 30), ST73 (50%, n=12 of 24), ST12 
(75%, n=3 of 4), ST10 (100%, n=2), ST14 (50%, n=1 of 2), ST2278 (33.3%, n=1 of 3) all had 
higher ESBL carriage levels in the bacteraemia isolates, whilst ST95 (46.1%, n=6 of 13) and 
ST69 (20%, n=1 of 5) showed comparable or lower levels than their UTI counterparts. 
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Figure 3. 9: UTI E. coli population minimum spanning tree with ESBL carriage. The figure presents ESBL carriage by the UTI E. coli isolates 
mapped on the different STs. We notice that only Nineteen STs out of the total sixty three STs (30.1%) of the UTI population were ESBL positive 
(Alhashash, et al., 2013).   
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Figure 3. 10: Bacteraemia E. coli population minimum spanning tree with ESBL carriage. The figure presents ESBL carriage by the 
bacteraemia E. coli isolates mapped on the different STs. Thirty STs out of the total fifty eight STs (51.7%) of the bacteraemia population were 
ESBL positive which is significantly higher (51.72%, 30.1%, p=.016) than the ESBL carriage of UTI STs (Alhashash, et al., 2013). 
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3.2.5 Reduction in diversity in the bacteraemia population is not associated with 
selection for bacteria with a specific VAG profile 
VAGs of all the E. coli isolates from the collected samples of bacteraemia and UTI were 
screened by multiplex PCR (Figure 3.11). 
 
Figure 3. 11: VAGs multiplex PCR gel image for screening of bacteraemia and UTI 
populations. The figure shows an example of the VAG multiplex PCR screening for the bacteraemia 
and UTI populations. 100bp DNA ladder was used (M). Lanes 1-14 represents samples U9-U22. This 
gel image represents pool1 of the VAGs PCR screening for the genes PAI, papA, fimH, papEF, ibeA. 
All E.coli isolates from the two clinical groups of bacteraemia and UTIs were carrying similar 
high percentages of fimH (97.1%/97.6%), fyuA (92.1%/91.2%), kpsMTII (83.6%/79.2.6%), 
PAI (76.4%/73.6%) and traT (70.7%/64%) as demonstrated in Figure 3.12. Significantly 
higher acquisition of iutA, papA, papEF, papG allele II and papG II,III were observed in the 
bacteraemia E.coli  population compared to UTI (P=0.006 95% confidence interval is ±5.3, 
P=0.016 95% confidence interval is ±5.8, P=0.001 95% confidence interval is ±5.7, P≤0.001 
95% confidence interval is ±5.5 and P=0.006 95% confidence interval is ±5.9 respectively). 
Significantly higher acquisition of sfaS in the UTI population was observed (p=0.005, 95% 
confidence interval is ±4.5). 
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Figure 3. 12: Percentages of VAGs carriage of the bacteraemia and UTI populations. The figure presents VAGs multiplex PCR screening 
results of all the isolates from the clinical samples of bacteraemia and UTI. ( * ) Significantly higher acquisition of iutA, papA, papEF, papG 
allele II and papG II,III were observed in the bacteraemia E.coli  population compared to UTI (P=0.006, P=0.016, P=0.001, P≤0.001 and 
P=0.006 respectively). Significantly higher acquisition of sfaS in the UTI population was observed (p=0.005). 
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The papA, papEF, papG allele II papG II,III and iutA VAGs were analysed with reference to 
the main STs of the two clinical populations for their potential to be more associated with the 
bacteraemia population but inconsistent results were obtained (Figure 3.13). Bacteraemia 
ST131 isolates exhibited higher carriage than the UTI ST131 isolates for papA (41%/11%), 
papEF (34%/0%), papG allele II (34%/11%) and papG II, III (34%/11%). Slightly higher 
carriage by bacteraemia ST73 isolates than UTI ST73 isolates was observed for papA 
(70%/62%), papG allele II (74%/56%) and iutA (77%/62%). However, lower carriage by 
bacteraemia ST95 isolates than UTI ST95 isolates was observed for papA (71%/83%), papG 
II,III (71%/83%) and papG allele II (71%/83%) except iutA (64%/33%). Other STs such as 
ST12 isolates from bacteraemia (n=4) and UTI (n=1) exhibited (100%) carriage of  papA , 
papEF and papG II,III,  while ST10 isolates from bacteraemia (n=2) and UTI (n=3) possessed 
none of these VAGs. Variable VAGs carriage patterns were observed in the rest of the STs. 
Overall, the VAGs data of the two clinical subsets of bacteraemia and UTI were found equally 
distributed with no statistically significant difference (p=0.675). One interesting finding is that 
ST73 E. coli isolates from both the bacteraemia and UTI populations have almost identical 
carriage of all the VAGs tested (Figure 3.13).   
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Figure 3. 13: Percentages of VAG carriage of the main STs in the bacteraemia and UTI 
populations. The figure displays a heat map of the percentages of VAGs carriage of the main 
STs of the UTI (A) and the bacteraemia (B) sample. 
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3.3 Discussion 
An earlier published study by our research group in the year 2011 reported that E.coli isolated 
from UTI infections were resistant to front line antibiotics with increased resistance to 
ciprofloxacin and trimethoprim (Croxall, et al., 2011b). Similar levels of antibiotic resistance 
were observed in E. coli UTI isolates in this study, but more importantly, higher levels of 
antimicrobial resistance were observed in bacteraemia E. coli isolates in all the antibiotics 
tested with higher significant resistance to ciprofloxacin and cefradine. Resistance to 
ciprofloxacin by bacteraemia E.coli isolates has been reported in many studies which 
concluded that these elevated levels of resistance were observed in community acquired E.coli 
infections due to drug misuse in outpatients and increased prescription which selected for 
resistant mutants (Cooke, et al., 2010; Sahuquillo-Arce, et al., 2011). 
 
When levels of multi-drug resistance, measured by resistance to different classes of antibiotics, 
were compared (Figure 3.3) there was a clear increase in the levels of multidrug resistance in 
the bacteraemia population. The demonstration of a multi-drug resistance phenotype in ExPEC 
is primarily associated with carriage of ESBLs. Not only was carriage of CTX-M, OXA, and 
SHV significantly higher in the bacteraemia population, but so too was phenotypic 
demonstration of the ESBL phenotype using the double disc diffusion method. This raises great 
concerns as ESBL E.coli bacteraemia is being increasingly associated with mortality. 
Significantly high mortalities due to ESBL producing E.coli bacteraemia were recorded 
compared to mortalities due to non ESBL producing E. coli bacteraemia (Melzer and Petersen, 
2007). In fact, infection with an ESBL producing E.coli isolate was one of the predictors of 
mortality due to community acquired E.coli bacteraemia (Kang, et al., 2010). 
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New information about the structure of E. coli populations from bacteraemia and UTI in the 
region were obtained by MLST. The previous study by our research group described a diverse 
UTI E.coli population with ST131 being the main ST. The UTI E. coli population in the current 
study was also found to be diverse, but with ST73 as the main ST along with other STs namely 
ST131, ST69, ST95, ST404 and ST10. Different prevalent STs were observed in the 
bacteraemia E. coli population with a reduction in diversity and three dominant STs, ST131, 
ST73 and ST95 that are commonly associated with human disease (Manges, et al., 2008). An 
overview of the minimum spanning trees of the two populations mapped with ESBL carriage 
revealed that 51.72% of the bacteraemia STs contain ESBL positive isolates compared to 30.16% 
of the UTI STs.  These data provide strong support for the hypothesis that antimicrobial 
resistance is a driving force for the reduction in diversity within the bacteraemia population of 
ExPEC. Such an observation has recently been made in a hospital population of Enterococcus 
faecium isolates (Willems, et al., 2012), where the circulation of a restricted population of 
highly antimicrobial isolates of low level genomic diversity were identified as causing an 
outbreak in a hospital. 
 
The two populations of bacteraemia and UTI were screened for VAG carriage with the aim of 
identifying a specific group of VAGs associated with bacteraemia isolates that may explain 
this reduction of diversity. VAG screening revealed high levels of carriage by all the E. coli 
isolates of fimH (type 1 fimbriae), fyuA (yersinibactin siderophore receptor), kpsMTII (group 
II capsule), PAI (pathogenicity associated island marker) and traT (serum resistance), which is 
in agreement with a previous study by our research group investigating ExPEC isolates from 
community and hospital acquired UTI (Croxall, et al., 2011). This is expected as the 
aforementioned VAGs are well described ExPEC associated VFs (Bien et al., 2012). 
Significantly higher carriage of sfaS, which encodes for the S fimbriae adhesin was observed 
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in the UTI isolates compared to the bacteraemia isolates. S fimbriae is reported to be associated 
with binding to distal tubule and glomerular epithelium of the kidney leading to upper urinary 
tract infections and pyelonephritis (Johnson and Stell, 2000; Jacobsen et al., 2008). Loss of this 
VF by the bacteraemia E. coli isolates may be beneficial as they will not attach to the kidney 
epithelium and be free to gain access to the bloodstream. 
       
A set of VAGs consisting of iutA (aerobactin siderophore receptor), papA (P fimbriae major 
subunit), papEF (P fimbriae associated), papG allele II (P fimbriae internal regions) and papG 
II,III (P fimbriae flanking regions) were found significantly more in the bacteraemia E.coli  
population compared to UTI. Aerobactin siderophore and P fimbriae adhesin are documented 
as bacteraemia virulence factors and are associated with upper UTI infection and kidney 
damage (Ron, 2010; Bien et al., 2012). ST404 displayed a good example of a bacteraemic ST 
carrying the documented bacteraemia virulence factor P fimbriae adhesin which was absent in 
all the UTI ST404 isolates. The carriage of the aforementioned set of VAGs was compared 
across all the STs in the E.coli populations of the two clinical samples of bacteraemia and UTI 
with the aim of identifying bacteraemia specific VAGs but varied profiles were observed with 
no association with specific STs. One example is papG allele II which was described as 
significantly prevalent in E. coli bacteraemia originating from upper UTI and a crucial trait for 
reaching the kidney (Moreno et al., 2005, Wright et al., 2007), was found completely absent in 
the bacteraemia and UTI ST10 and ST404 isolates. Similarly, previous work by our group 
found that the most prevalent ST131 in the urine population had variable VAGs profiles and 
failed to identify virulence specific genes that associate with a particular ST (Croxall, et al., 
2011). 
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In conclusion, this study has described a difference in the epidemiology of E. coli populations 
of bacteraemia and UTI in terms of their phenotypic and genotypic characteristics. 
Significantly high numbers of ESBL positive and MDR E.coli isolates were observed in 
clinical cases of bacteraemia. Furthermore, 21.4% of the bacteraemia E.coli isolates were 
ST131. Interestingly ST73 E. coli in the UTI population are on the increase and are the most 
prevalent ST compared to the previous study of our group. They are also one of the three 
dominant STs of bacteraemia. When VAG carriage in ST73 isolates was compared in the two 
populations, they were almost identical while the ESBL carriage is significantly higher in the 
bacteraemia ST73 isolates (50%) compared to the UTI (18%). 
 
We provide strong evidence that the presence of drug resistance driven by ESBL carriage 
appears to be a driving pressure resulting in a reduction in population diversity in the 
bacteraemia isolates. This observation carries significance on several fronts, not least of all due 
to the fact that numerous evolutionary bottleneck selection episodes in bacteria have resulted 
in lineages of genetically monomorphic pathogens which become human host restricted and 
more pathogenic, with classical examples in Yersinia, Salmonella, Bacillus, and Francisella 
(Achtman, 2012). There is a pressing need now to understand the population genomics of this 
set of isolates to help us identify any other factors which may be driving this selection effect, 
and to fully gauge the true extent of the diversity in the predominant bacteraemia sequence 
types, similar to the work which has identified circulation of genetically homogeneous strains 
of ST131 in health care facilities (Clark, et al., 2012). 
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Chapter Four 
Comparative genome analysis of ST73 isolates from clinical 
samples of UTI and bacteraemia 
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4.1 Introduction 
 
4.1.1 Importance of comparative genome analysis 
E. coli isolates from different geographical regions and hosts have heterogeneous genomes and 
may differ in size by up to 1 Mbp (Bergthorsson and Ochman, 1998).  This diversity in the 
genome of E. coli species is due to deletion or acquisition of genetic elements by horizontal 
gene transfer. It was found that horizontal gene transfer events were observed in about 18% of 
all the open reading frames (ORFs) of MG 1655 E. coli (Lawrence and Ochman, 1998). In fact, 
horizontal gene transfer is largely accountable for the evolution of different bacterial 
pathotypes, as many VAGs are located on mobile genetic elements such as plasmids, 
bacteriophages and PAIs (Hacker and Kaper, 2000). Whole genome sequencing has allowed 
for the ability to comprehensively characterize the genetic diversity and evolution of many 
related strains which was very difficult before (Metzker, 2009). The characteristics of E. coli 
species of being both a commensal and a versatile pathogen made it the perfect candidate for 
such studies (Tenaillon et al., 2010). For example, whole genome comparisons of uroseptic E. 
coli CFT073, EHEC strain EDL933 and commensal E. coli MG1655 revealed large diversity 
between their genomes, as they only shared 39.2% of their combined nonredundant proteins. 
Furthermore, when the CFT073 E. coli genome was compared to two other UPEC strains large 
differences were observed in their PAIs. This indicates that the different ExPEC strains had 
common vertically evolved genes in their backbone, but had different horizontal gene transfer 
events dictating their PAIs (Welch et al., 2002). Another application of comparative whole 
genome analysis is in the investigation of disease outbreaks and bacterial transmission 
mechanisms. One example is the investigation of a putative disease outbreak of methicillin 
resistant Staphylococcus aureus (MRSA) in a special care baby unit in 2011 (Harris et al., 
2013). Twelve infants were infected in a 6 months period and due to the high discriminatory 
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ability of whole genome analysis it was confirmed that MRSA carriage by a member of the 
staff at the special baby care unit was the source of the infection which allowed for the infection 
to persist. 
A more related example of the importance of whole genome sequencing in outbreaks 
investigation is the identification of the hybrid E. coli O104:H4 strain in the German outbreak 
in 2011 (Bielaszewska et al., 2011). It resembled enterohaemorrhagic E. coli (EHEC), Shiga 
toxin encoded by stx2 prophage. On the other hand, by comparative genome analysis O104:H4 
E. coli strain was closely related to enteroaggregative E. coli (EAEC), particularly strain 55989 
responsible for chronic diarrhoea in Central Africa (Mossoro et. al., 2002; Bielaszewska et al., 
2011). One of the plasmids of O104:H4 strain called (pAA) is associated with typical (EAEC) 
adherence that is regulated by the specific (EAEC) virulence regulator AggR. Another (EAEC) 
related virulence factor released by O104:H4 strain is Pic which is a mucinase that enhances 
intestinal colonization (Richter et al., 2014). Furthermore, O104:H4 also contain an ESBL 
plasmid encoding a bla-CTXM-15 and bla-TEM (Yamaichi et. al., 2014).         
 
4.1.2 Pangenome analysis 
To be able to characterize and accurately compare and determine the entire gene contents of 
multiple genomes, the pangenome approach was developed (Tettelin et al., 2005). The 
pangenome, (or whole genome) consists of a core genome which includes all the genes present 
in all the strains in the analysis, a dispensable (or accessory) genome which includes the genes 
present in some of the strains in the analysis and a group of strain specific genes (Tettelin et 
al., 2008). This means that each time when a new genome is included in the analysis new strain 
specific genes are added and the size of the pangenome increases. The core genome is believed 
to contain the genes that encode for basic biological and phenotypic functions while the 
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accessory genome encodes for the species diversity and provides selective advantages such as 
niche adaptation, antibiotic resistance and virulence factors. Therefore pangenome analysis is 
useful in understanding the bacterial population structure, adaptation and evolution as well as 
providing targets for vaccines and antibiotics (Tettelin et al., 2008). Pangenome analysis can 
be used to determine the gene pool of genomes from the same species (Tettelin et al., 2005), 
or from different species (Gordienko et al., 2013). It can also analyse differences in the gene 
content of strains from the same species but of different pathotypes or groups (Rasko et al., 
2008). 
 
4.1.3 Application of genomics to study E. coli ST131 
Population genetics analysis revealed that the recent epidemic spread of ST131 E. coli isolates 
was driven by a predominant subclone named H30, which was found associated with high 
carriage of the fimH30 allele encoding type 1 fimbriae (FimH) (Johnson et al., 2013). Price et 
al. (2013) constructed a single nucleotide polymorphism (SNP) whole genome phylogeny of 
105 ST131 E. coli isolates from 5 different countries. The CTX-M-15 producing and 
fluoroquinolone resistance phenotypes were overlaid on the phylogenetic tree to investigate the 
evolutionary origins of this dominant pathogen. The resulting phylogenetic tree revealed a 
subclade consisting of strains carrying the FimH30 allele, designated H30, as well as carrying 
gyrA and papC alleles and O type. 95% of the fluoroquinolone resistant and all the ESBL 
producing isolates fell within this H30 clade. To further investigate their history of evolution, 
all the genomes of H30 isolates were aligned separately against ST131 reference strain NA114 
and a high resolution phylogeny was produced. The resulting tree revealed that the acquisition 
of fimH30 allele occurred before fluoroquinolone resistance acquisition followed by a large 
clonal expansion. This fluoroquinolone resistant subclone was named H30-R to differentiate it 
from the ancestral fluoroquinolone sensitive H30 clade. Interestingly, 91% of the CTX-M-15 
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producing isolates formed a subclade within the H30-R and was named H30Rx referring to its 
extensive resistance. This study concluded that the highly prevalent pandemic CTX-M-15 
producing ST131 isolates occur due to the clonal expansion of the H30-Rx subclone (Price et 
al., 2013). The global dissemination of ST131 E. coli was also confirmed in another study 
performed by Petty et al. (2014). 95 E. coli ST131 strains isolated between 2000 and 2011 from 
six different geographical locations were investigated in terms of whole genome analysis, 
virulence associated genes (VAGs) and CTX-M gene carriage (Petty et al., 2014). Phylogenetic 
analysis revealed a single distinct lineage of ST131 E. coli from the other ExPEC in the study. 
Within the ST131 E. coli lineage three closely related sublineages were identified named A, B 
and C. The most prevalent sublineage C (79% of the strains) was characterized by 
fluoroquinolone resistant ST131 E. coli isolates, the majority of which were CTX-M-15 
positive confirming the H30-Rx subclone, and were found to be geographically dispersed 
(Petty et al., 2014).           
 
4.1.4 Rational and aim 
We proposed in Chapter 3 that carriage of ESBL genes by some E. coli strains may offer a 
selective advantage accounting for their dominance and progression to bacteraemia. To further 
investigate this hypothesis, we aimed to perform comparative genome analysis of a group of 
ESBL positive and ESBL negative E. coli strains belonging to the same dominant sequence 
type from both the bacteraemia and UTI groups in our collection. These detailed comparative 
genomics aimed to determine whether the increased prevalence of certain STs and the increased 
ESBL carriage in the bacteraemia strains were due to the circulation of successful circulating 
clones as in ST131. The comparative genome analysis also aimed to determine whether the 
bacteraemia strains were associated with specific bacteraemia associated loci or is ESBL 
carriage the major determinant for their progression to more serious disease. ST131 was the 
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most dominant bacteraemia ST, but it was not selected in our investigation. This is because 
ST131 is well-defined and characterised in the literature (Johnson et al., 2013; Price et al., 
2013). Previous work by our pathogen research group at NTU has also contributed to defining 
this pandemic ST131 clone (Clark et al., 2012). Instead we chose to study ST73 E. coli strains 
that are also dominant in the bacteraemia population in Nottingham and the most prevalent ST 
in the UTI population. Therefore, it was interesting to investigate whether the high prevalence 
of ST73 was also due to a successful circulating clone as in ST131. Sequencing of isolates 
belonging to ST73 was elected for two more reasons. First, there is little research in the 
literature describing clinical E. coli ST73 isolates and any research in this field will provide 
new knowledge on this widely isolated ST. Secondly and more importantly, ST73 fitted with 
the hypothesis that ESBL acquisition favoured selection or advantage towards bacteraemia as 
50% of the bacteraemia ST73 strains were ESBL positive compared to 18% of the UTI ST73 
strains. Specific aims in this investigation were: 
A) Construction of SNP based whole genome phylogenetic tree to determine the relatedness 
of the investigated blood and urine ST73 E. coli strains. 
B) Comparative whole genome analysis of all the ST73 E. coli strains to identify bacteraemia 
specific loci or ESBL carriage specific loci. 
C) Plasmid profiling of all the ESBL positive ST73 E. coli isolates to identify plasmid 
similarity. 
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4.2 Materials and Methods 
 
4.2.1 Strains 
A total of twenty-two strains of ST73 E.coli isolates from clinical samples of bacteraemia and 
UTI were selected for sequencing. The group consisted of ten ESBL positive bacteraemia E. 
coli, two ESBL negative bacteraemia E. coli, three ESBL positive UTI E. coli and seven ESBL 
negative UTI E. coli all belonging to sequence type ST73. The selected numbers of strains 
represented the ratio of positive to negative ESBL carriage in the two populations. Details of 
the selected E. coli ST73 isolates are provided in table 4.1A and Table 4.1B. In addition, a 
suitable reference E. coli genome was needed to perform many of the analyses in this chapter. 
We chose the E. coli CFT073 genome (NCBI Reference Sequence: NC_004431.1) as a 
reference genome since it belonged to sequence type ST73 and is a urosepsis isolate (Welch et 
al., 2002). 
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Table 4. 1A: Bacteraemia ST73 E. coli isolates selected for sequencing   
Strain ESBL type* GM CPM CAZ MEM PTZ AUG TM CIP CRD CRD AP 
B10 CTXM-15  R      R   R 
B14 Negative R           
B18 CTXM-15   R   R   R  R 
B29 CTXM-15  R      R   R 
B36 SHV+CTXM-15   R  R      R 
B40 SHV+CTXM-15  R     R    R 
B72 CTXM-15      R  R R  R 
B73 CTXM-15  R      R   R 
B84 SHV+CTXM-15  R      R   R 
B91 CTXM-15   R   R   R  R 
B102 Negative R           
B134 CTXM-15+OXA   R  R R R    R 
*Isolates were screened by PCR for ESBL carriage as described in section 2.4. CTXM positive PCR products 
were sent and sequenced by Source Bioscience LifeSciences. Antibiotic susceptibility profiles were performed as 
described in section 2.3: Resistant (R), gentamicin (GM), cefpodoxime (CPM) ceftazidime (CAZ), meropenem 
(MEM), piperacillin-tazobactam (PTZ), co-amoxiclav (AUG), trimethoprim (TM), ciprofloxacin (CIP), cefradine 
(CRD), nitrofurantoin (NI), and ampicillin (AP). 
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Table 4. 1B: UTI ST73 E. coli isolates selected for sequencing 
Strain ESBL type* GM CPM CAZ MEM PTZ AUG TM CIP CRD CRD AP 
U1 Negative     R       
U7 Negative            
U21 Negative           R 
U24 Negative            
U30 Negative            
U36 Negative       R    R 
U42 CTXM-15  R       R  R 
U48 Negative            
U50 CTXM-15      R   R  R 
U76 SHV+CTXM-15  R   R R R R   R 
*Isolates were screened by PCR for ESBL carriage as described in section 2.4. CTXM positive PCR products 
were sent and sequenced by Source Bioscience LifeSciences. Antibiotic susceptibility profiles were performed 
as described in section 2.3: Resistant (R), gentamicin (GM), cefpodoxime (CPM) ceftazidime (CAZ), 
meropenem (MEM), piperacillin-tazobactam (PTZ), co-amoxiclav (AUG), trimethoprim (TM), ciprofloxacin 
(CIP), cefradine (CRD), nitrofurantoin (NI), and ampicillin (AP). 
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4.3 Results 
4.3.1 Sequences assembly by Velvet and PAGIT software 
Improved quality genome assemblies were created for all twenty two ST73 E. coli isolates 
using Velvet and PAGIT (sections 6.2 and 6.3 of appendix). Assembly metrics are described 
in Table 4.2. 
Table 4. 2: Details of the twenty two sequenced ST73 E. coli isolates genomes after 
PAGIT assembly. 
Strain Sequence size (bps) Number of contigs N50 (bps) 
B10 5173276 106 108731 
B14 5099552 158 113475 
B18 5120683 125 122417 
B29 5264174 168 101820 
B36 5191523 152 125321 
B40 5257611 165 103549 
B72 5158804 110 134654 
B73 5150717 156 123129 
B84 5182704 137 134972 
B91 5155911 197 79515 
B102 5075956 160 87164 
B134 5230535 154 116039 
U1 5243352 151 123112 
U7 5176031 145 126228 
U21 5145668 162 113459 
U24 5120446 147 110560 
U30 5287542 160 139416 
U36 5162072 138 114804 
U42 5188710 155 106920 
U48 5080928 112 113440 
U50 5256879 145 117621 
U76 5189037 140 133761 
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4.3.2 SNP based phylogeny 
SNP analysis of the twenty-two ST73 genome sequences showed a high level of polymorphism 
of 15,278 SNPs between the strains. The diversity is clearly observed in Figure 4.1 where there 
is no apparent clustering of bacteraemia strains, or UTI strains but rather they are randomly 
distributed around the phylogenetic tree. This rules out the probability of an E. coli ST73 clone 
outbreak in our bacteraemia or UTI clinical samples. When the ESBL carriage was mapped to 
the tree, ESBL positive strains were also randomly distributed across the tree. This also 
confirms that the increase of ESBL carrier strains, like the increase in the number of ST73 in 
the bacteraemia population, is not due to a circulation of a successful strain.  
When the relationship between the twenty-two strains in the phylogenetic tree was examined 
in terms of ESBL carriage, two potential groups were recognised on opposite sides of the tree 
as indicated by circles in Figure 4.1. The first potential group consisted of seven ESBL positive 
strains, five from bacteraemia (B29, B73, B36, B84 and B10) and two from UTI (U42 and 
U76). The second potential group consisted of four ESBL positive strains, three from 
Bacteraemia (B18, B72 and B134) and one from UTI (U50). These potential groups were 
investigated further in terms of the SNPs distances between themselves and their neighbouring 
strains. 
 
 
92 
 
 
Figure 4. 1: SNPs based Phylogenetic tree of the twenty two E. coli ST73 against E. coli 
CFT073 reference genome using maximum likelihood method. The tree displays a diverse 
group of E. coli ST73 strains without clear clustering. Bacteraemia isolates coloured red, UTI 
isolates coloured blue, ESBL positive strains indicated by a star sign, yellow circles define 
potential ESBL positive group of strains and a blue circle define another potential ESBL 
positive group of strains. 
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4.3.2.1 Investigation of pairwise distance 
Pairwise distance analysis was performed to determine the number of SNPs between all the 
strains and the reference genome in relation to each other. Table 4.3 presents the pairwise 
distance with colour scaling depending on the number of base differences between the strains 
where higher numbers correlate with darker colour. A rectangular layout of the SNP based 
phylogenetic tree is displayed in Figure 4.2. We noticed that the distances between the four 
strains (B134, U50, B72 and B18) were very large ranging between 1453 and 3119 SNPs, 
which shows a high level of heterogeneity between their genomes. The other group of the seven 
ESBL positive strains (B10, U42, B84, U76, B36 B73 and B29) was found to be slightly more 
related to each other as the SNPs distances between them were low ranging from 416 to 989 
bases. In both cases MDR ST73 do not appear to be a successful circulating clone like ST131 
observed in the previous study by our group where nine of the ten sequenced strains shared 
only 10 to 60 SNPs between them (Clark et al., 2012).            
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Table 4. 3: Pair wise distances matrix measured by the number of SNPs between the strains 
 
 
 
 
 
 
 
 
 
 
Table 4.3 displays the number of SNPs bases between the strains. The higher the number of SNPs between any two strains the more distantly related to each other.  
 
 Ref U48 U50 B84 B29 U42 B14 B40 B73 U24 U30 U1 U76 B18 U36 B72 U7 B10 B36 B91 B102 U21 B134 
Ref                        
U48 1887                       
U50 1874 3109                      
B84 1800 2475 2901                     
B29 1079 1966 2411 1079                    
U42 1223 2046 2523 989 564                   
B14 1589 2596 2836 2658 2074 2210                  
B40 1232 2278 2443 2337 1663 1779 2206                 
B73 1551 2011 2772 1133 790 836 2350 1896                
U24 2471 3679 3743 3510 3061 3187 3514 3196 3427               
U30 1598 2458 2696 2421 1932 2020 2412 816 2017 3340              
U1 2117 2916 3077 2898 2417 2513 2925 1276 2525 3792 1039             
U76 1724 2336 2870 728 979 841 2539 2209 1037 3468 2309 2776            
B18 2235 3497 2840 3230 2727 2869 3294 2868 3085 3831 3047 3520 3198           
U36 1252 2359 2712 2093 1874 1825 2395 2117 2216 3355 2424 2936 2068 3188          
B72 2182 3262 1453 3173 2664 2777 3145 2669 2997 3714 2854 3234 3119 3119 2936         
U7 2168 3444 2781 3153 2656 2795 3224 2814 3042 3676 3022 3432 3136 1364 3107 3008        
B10 1207 2032 2487 944 499 416 2175 1736 811 3166 2027 2479 840 2861 1833 2772 2788       
B36 1664 2282 2814 687 901 779 2501 2155 941 3377 2258 2732 626 3130 2023 3061 3051 773      
B91 3854 4848 5082 5025 4545 4617 4502 4531 4771 5711 4752 5201 4983 5483 4361 5221 5387 4611 4932     
B102 2828 3942 3505 3697 3192 3338 3786 3484 3545 3923 3616 4075 3695 3565 3727 3413 3471 3339 3618 5963    
U21 3028 4142 4013 4139 3587 3705 4134 3611 3949 4392 3936 4288 4123 4248 3913 3995 4141 3686 4090 6026 3206   
B134 1506 2948 2282 2697 2103 2217 2616 2206 2503 3427 2427 2853 2606 2690 2433 2634 2435 2221 2545 4757 3443 3798  
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Figure 4. 2: pairwise distances of SNPs based phylogenetic tree of the 22 strains of E. coli ST73 against CFT073 E. coli reference genome. 
Two groups of ESBL positive strains highlighted in different colours and the arrows represent the SNPs distance between neighbouring strains.
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4.3.3 Comparative genome analysis 
Comparisons between the genomes of all twenty-two ST73 E. coli strains aimed to investigate 
whether there were genomic regions or loci unique to the bacteraemia ST73 E. coli strains. 
Comparisons also aimed to investigate whether regions or loci were specific only to ESBL 
carrier ST73 E. coli strains from bacteraemia and UTI clinical samples. Comparative genome 
analysis was made using Gegenees (Agren et al., 2012). 
 
4.3.3.1 Determination of the core and pangenome 
The determination of the core and pangenome of all the twenty-two ST73 E. coli strains was 
performed by Gegenees software (Gegenees.org, 2014). The pangenome was constructed by 
fragment analysis approach where fragments of all the genomes were compared to each other 
by pairwise BLAST of their nucleotides (BLASTN) for similarities and only unique fragments 
were added gradually to the pangenome (Figure 4.3). The pangenome is represented on the top 
of the figure by a black horizontal line which consisted of 8,309,000 bps in 41545 fragments 
(each fragment consists of 200 bps) divided by many subsequences. The total number of genes 
in the pangenome was 10,095 genes reflecting the diversity of the ST73 strains. In Figure 4.3, 
several black lines are displayed below the pangenome line representing the twenty two 
genomes of ST73 E. coli strains in the analysis. Fragments of each genome in the analysis were 
compared to the pangenome on the top and when similar fragments were identified a dot is 
plotted over the genome line. The collection of dots similar to the pangenome form a peak. The 
green peaks on the left of each genome in Figure 4.3 represent the core genome in the analysis 
which consists of genomic regions shared by all the strains under investigation. The total 
fragments contained in the pangenome were 41545 and the core genome represented 59.8% of 
the pangenome (24,826 fragments). To the right of the core genome of each strain are the 
accessory genomic regions showing a high level of genomic diversity between the twenty-two 
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strains in the analysis (Figure 4.3). This is in line with published studies of E. coli pangenome 
analyses. Pangenome analysis of intestinal, ExPEC and commensal E. coli showed an open 
pangenome model where approximately 50% of the gene content represented the core genome 
and each new genome sequence contributed about 300 novel genes ( Lloyd et al., 2007; Rasko 
et al., 2008). This suggests an open pangenome in ST73 E. coli in this project.        
 
Figure 4. 3: Overview of the core and pangenome analysis by Gegenees software. The 
figure displays the pangenome at the top by a horizontal black line. Below it are black lines 
representing all the twenty two ST73 E. coli strains under study. The peaks on top of each 
genome are colour coded red, orange, yellow and green according to the similarity of the 
fragment compared to the pangenome where red represents least similarity and green represents 
exact similarity. The green peaks on the left of each genome line represent the core genome in 
the analysis which contains similar genomic regions shared by all the genomes in the study. 
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4.3.3.2 Investigation of bacteraemia and ESBL carrier specific loci 
Using Gegenees software, all the genomes under investigation were fragmented and aligned 
using multithreaded pair-wise nucleotide comparisons (BLASTN). The alignment performed 
by Gegenees assigns an average score of the pair-wise comparisons of all the fragments against 
each other for each genome to determine their degree of similarity (Agren et al., 2012). These 
similarities were described in a matrix and were displayed in a heat plot (Figure 4.4). The 
visualisation of the whole genome alignments in the heat plot provided an overview of the 
phylogenetic relationship between the strains (Agren et al., 2012). We notice in Figure 4.4 that 
the same seven ESBL positive strains (B10, B29, B36, B73, B84, U42 and U76) which were 
identified earlier as being most similar to each other than the other strains were also found very 
similar in Gegenees alignment, indicated in the green colour and the high average BLASTN 
scores at the top of Figure 4.4.  
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Figure 4. 4: Heat plot display of Fragmented all-all comparisons of Gegenees software. 
The figure displays the similarities of the aligned twenty two genomes by as a heat plot and  
BLASTN (200/100) score matrix. We notice the green colour group of strains at the top (U42, 
U76, B10, B29, B36, B73 and B84) with the high average scores which indicate their similarity. 
The target strains or group (green colour), the background strains or group (red colour) and the 
reference strain from the target group (black colour) are displayed on the left.     
 
An important feature of the Gegenees software is the ability to analyse the alignment dataset 
to identify genomic regions specific or unique to a target group, also called target signature, 
when compared against a background group. For this purpose as seen in Figure 4.4, all the 
bacteraemia ST73 E. coli strains were selected as a target group to investigate bacteraemia 
specific signature, B134 strain was selected as a reference genome from the target group, and 
the ST73 UTI strains were selected as background group. Target specific loci or target signature 
analysis was performed by determining a biomarker score based on fragment comparisons of 
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the worst false positive in the background group against the worst false negative in the target 
group for each fragment in the reference genome (Agren et al., 2012).  The output of the target 
signature analysis is displayed in Figure 4.5. The highest value of the biomarker scores is 1, 
which indicates perfect conservation and no cross reaction and displayed in green colour. In 
Figure 4.5 two grey blocks are displayed and each of them are separated by a black line which 
represents a total of 52821 fragments of the reference genome used as a coordinate axis starting 
from the top rectangle on the left and ends in the bottom rectangle on the right. Two biomarker 
stringency options were applied where the biomarker scores for each fragment can be plotted 
against the reference coordinate axis displayed in Figure 4.5. The highest stringency option 
(max/min or 100% target group specific) is displayed above the reference axis and presents 
genomic regions or loci only specific to the target group. No target signature or conserved 
genomic regions were found specific only to the ST73 bacteraemia strains. For that reason and 
to investigate further, it was useful to select a more relaxed stringency option (max/average or 
80/20% target group specific) where a target signature may be identified but it may be absent 
or not conserved in all the bacteraemia ST73 strains. A large number of associated regions 
indicated by complete green columns were identified and they were defined as plasmid DNA 
shown on the right of the bottom rectangle (Figure 4.5). Small genomic regions in the middle 
were also identified. These highlighted regions were investigated further. These regions were 
found to be segments of unspecified sequences labelled with repeated N’s and the plasmid 
highlighted regions were found associated with conjugation proteins shared by all the isolates 
and of no particular interest other than ESBL genes. They were highlighted because Gegenees 
does not only identify presence or absence of genes but also identifies group specific alleles of 
CDS. Not all the sequenced bacteraemia ST73 strains were ESBL positive, hence specific loci 
associated with ESBL plasmids were not found in the high stringency conditions.   
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Figure 4. 5: Biomarker score overview of target specific loci (target signature) analysis 
by Gegenees software. The figure displays the output of the target specific loci analysis where 
all the bacteraemia strains were selected as a target group against a background of all the UTI 
strains. The black line in the middle of the two blocks represents the reference strain (B134) 
genome fragments starting from the top left and ends in bottom right. The reference genome 
size scale is displayed and a coloured biomarker scale is displayed where the highest score for 
completely unique region is 1 and coloured green. The high stringency option output is 
displayed above the reference coordinate axis in the two blocks with no target signature 
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identified. The less stringent option is displayed below the reference coordinate axis with large 
number of target specific regions or loci identified in the plasmid region. 
 
The target signature analysis was repeated for the twenty-two ST73 E. coli strains where all 
the ESBL positive strains from bacteraemia and UTI samples were selected as a target group 
against a background group of all the ESBL negative strains from bacteraemia and UTI samples. 
A similar analysis output was obtained where no target specific signature was identified except 
for the plasmid regions as described above. This validates our finding that genome specific 
regions or loci were found highly associated with the plasmid region in both tests for 
bacteraemia target signature and ESBL carrier target signature. 
 
4.3.4 Plasmid profiling by S1 PFGE 
Detection and sizing of the CTX-M plasmids carried by the ST73 E. coli was performed 
(Figures 4.6A and 4.6B). Different plasmids were found to be carried by most of the tested 
ST73 strains and some carried more than one plasmid. This finding rules out the possibility 
that the increased prevalence of ST73 in the bacteraemia population, associated with increased 
antibiotic resistance, is due to the dissemination of a single successful plasmid. The different 
plasmids and their relative sizes are summarized in Table 4.4. The CTX-M negative ST73 
strains showed no plasmid carriage by profiling with S1 PFGE (B14, U24 in Figure 4.6A and 
B102 in Figure 4.6B). Plasmids of the same sizes were found to exist in some strains, with an 
82 kb plasmid carried by B72 and B134; a 48.5 kb plasmid carried by B18 and U50; and a 33.5 
kb plasmid carried by (B18 and B72). The commonly occurring size of plasmid was 112 kb 
which was carried by B10, B29, B73, B84, U42 and U76 strains. Interestingly, these are the 
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same strains that were identified earlier by SNP based phylogeny (section 4.3.1) as being 
similar and grouping together (Figure 4.2).  
 
 
Figure 4. 6A: S1 nuclease PFGE gel image. The figure shows the different plasmids detected 
in the CTX-M carrier strains tested. On the left is low range DNA ladder and on the right is 
mid-range DNA ladder. C represents the positive control NCTC E. coli 13353. 
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Figure 4. 6B: S1 nuclease PFGE gel image. The figure shows the different plasmids detected 
in the CTX-M carrier strains tested. On the left is low range DNA ladder and on the right is 
mid-range DNA ladder. C represents the positive control NCTC E. coli 13353. 
 
Table 4. 4: List of the different plasmids and their size as determined by S1 PFGE 
S1 PFGE plasmid size Strain Name 
33.5 kb B18, B72 
48.5 kb B18, U50 
82 kb B72, B134 
112 kb B10, B29, B73, B84, U42, U76 
120 kb B91 
140 kb B40 
145 kb B36 
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4.3.5 Determination of plasmid types 
After the detection of the different plasmids for all the 13 ESBL harbouring ST73 E.coli strains 
from clinical samples of bacteraemia and UTI by S1 PFGE, it was important to determine the 
plasmid type of these plasmids to complete their profiles. The Plasmid Finder tool 
(www.cge.cbs.dtu.dk) was used to identify the plasmid replicons or incompatibility groups (Inc) 
that are specific regions responsible for plasmid replication (Szczepanowski et al., 2005; 
Carattoli et al., 2014). The Plasmid finder tool also assigns the reference plasmid from the 
NCBI database used to identify the plasmid under investigation (Carattoli et al., 2014). The 
sequences of all thirteen ESBL carrying ST73 E. coli strains from the clinical samples of 
bacteraemia and UTI were uploaded to the website and the results are displayed in Table 4.5. 
 
Table 4. 5: Plasmid Typing by Plasmid Finder tool 
Strain Plasmid Type 
(Inc)a 
Identity 
(%) 
Position in sequence Accession Number in 
NCBI 
B10 FIB(AP001918) 
Col156 
FII 
96% 
98% 
96% 
5031346-5032023 
5118210-5118363 
5180958-5181206 
AP001918 
NC_009781 
AY458016 
B18 Inconclusive 
B29 Col156 
FIB(AP001918) 
FII 
99% 
97% 
96% 
5049007-5049160 
5225976-5226657 
5291977-5292228 
NC_009781 
AP001918 
AY458016 
B36 FII 
Col156 
FIB(pB171) 
96% 
99 
81% 
5072669-5072918 
5152675-5152828 
5209650-5210108 
AY458016 
NC_009781 
AB024946 (pB171) 
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B40 FIA 
FIB(AP001918) 
100% 
97% 
5080891-5081278 
5153511-5154129 
AP001918 
AP001918 
B72 FII(pRSB107) 96% 5045924-5046185 AJ851089 
B73 Col156 
FII 
FIB(AP001918) 
99% 
96% 
97% 
5076791-5076944 
5102726-5102977 
5112600-5113281 
NC_009781 
AY458016 
AP001918 
B84 FII 
FIB(AP001918) 
Col156 
96% 
97% 
99% 
5063637-5063888 
5127437-5128118 
5225448-5225601 
AY458016 
AP001918 
NC_009781 
B91 FII(29) 
FIB(S) 
Col156 
100% 
80% 
99% 
4883713-4883971 
5122047-5122580 
5150722-5150875 
CP003035 (pUTI89) 
FN432031 
AP001918 
B134 FIB(AP001918) 
FII(p14) 
FIA 
98% 
86% 
100% 
4988225-4988906 
5120388-5120627 
5212914-5213276 
AP001918 
JQ418538 (p14) 
AP001918 
U42 FIB(AP001918) 
Col8282 
Col156 
Col(MG828) 
97% 
90% 
99% 
92% 
5019853-5020534 
5083549-5083746 
5166911-5167064 
5185730-5185991 
AP001918 
DQ995353 
NC_009781 
NC_008486 
U50 FII 100% 5002792-5003045 AY458016 
U76 Col156 
FII 
FIB(AP001918) 
99% 
96% 
96% 
4991211-4991364 
5037803-5038054 
5102247-5102925 
NC_009781 
AY458016 
AP001918 
a The numbers between brackets after the Inc type refer to the NCBI accession number of the sequence used to Identify the 
plasmid type by Plasmid Finder tool (Carattoli et al., 2014) 
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The first thing we confirmed from Figure 5.4 was that the positions of the plasmid sequences 
were at the end of our genome assemblies which is where we expected them to be after PAGIT 
assembly. PAGIT reassembles the genomes according to the reference genome. Since the 
reference genome of CFT073 has no plasmid in the sequence, PAGIT reorders the unmatched 
sequences of plasmids at the end of the genomes. Some strains were found to have more than 
one Inc type in the same plasmid, which occurs in ExPEC (Karisik et al., 2006; Johnson and 
Nolan, 2010). We notice that the Inc type determined for all of the plasmids in our study 
belonged to IncFIA, IncFIB or IncFII which is very significant as these IncF types are well 
documented in the literature as encoding CTX-M-15 among other ESBLs conferring multidrug 
resistance (MDR) and virulence factors (Karisik et al., 2006; Villa et al., 2010; Carattoli, 2013). 
One of the most important types of plasmids found in our group was FII which had 96% 
homology in strains B10, B29, B36, B73, B84, U50, and U76. There was significant identity 
to pC15-1a which is an IncFII plasmid encoding CTX-M-15 ESBL first sequenced by Boyed 
et al. (2004) in Canada. It has also been found carrying CTX-M-15 in the United Kingdom 
(Karisik et al., 2006) and is strongly associated with ST131 producing CTX-M-15 ESBLs from 
many other countries in Europe (Novais et al., 2012). IncFII plasmids can also be found in the 
same plasmids with IncFIB regions as was the case in our strains as seen in Table 4.4 (TOBE 
et al., 1999; Karisik et al., 2006). Another well documented resistance plasmid type found in 
our strains was the FII(pRSB107) harboured by the strain B72 with 96% homology. It was 
characterized as containing IncFII, IncFIA and IncFIB replicons, MDR properties and 
virulence associated functions (Szczepanowski et al., 2005). Other studies in many countries 
have published the association of pRSB107 plasmids and homologous plasmids with the 
incidence and spread of CTX-M-15 and other CTX-M ESBLs (Carattoli et al., 2007; Novais et 
al., 2007; Coque et al., 2008;). Homologous plasmids to FIB(AP001918) plasmid were also 
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associated with hospital SHV ESBL infections in Poland (Zienkiewicz et al., 2007) and this 
plasmid was identified with 97% homology in SHV carrier strains B40, B84 and U76 (Table 
4.1A and Table 4.1B). 
Referring to Tables 4.3 and 4.4, the plasmid types of the thirteen ESBL positive ST73 E. coli 
strains were compared to those detected with S1 PFGE. Interestingly, five E. coli ST73 strains 
were found to have the same plasmid type determined by Plasmid Finder tool with the same 
size from S1 PFGE. These strains were B10, B84, U76, B73 and B29 which have a 112 kb 
plasmid with exactly the same plasmid type combination of the significant resistant plasmid 
FII in addition to FIB(AP001918) and col156. Although the exact sequence of the plasmid is 
not available for confirmation, with the same size and exact plasmid type (with homology more 
than 95% by Plasmid Finder tool), this 112 kb plasmid is very likely to be identical in these 
strains. These five strains were members of the group of seven similar strains mentioned in 
sections 4.3.1 and 4.3.2 with the exception of B36, which contains an 145 kb plasmid, and U42 
which has a 112 kb without an IncFII replicon. These plasmid types and the other resistance 
plasmids from plasmid Finder were combined with the different plasmid sizes from S1 PFGE 
in Table 4.5 and then mapped on to the SNP phylogenetic tree in Figure 4.7. 
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Table 4. 6: Main plasmid types from Plasmid Finder with S1 PFGE profiles 
S1 PFGE 
plasmid size 
Strain Plasmid Type from Plasmid 
Finder tool 
33.5 kb 
B18 
B72 
Not determined 
FII(pRSB107) 
48.5 kb 
B18 
U50 
Not determined 
FII 
82 kb 
B72 
B134 
FII(pRSB107) 
FII(p14) and FIA 
112 kb B10, B29, B73, B84, U76 FII, FIB(AP001918) and Col156 
120 kb B91 FII(29) and FIB(S) 
140 kb B40 FIA and FIB(AP001918) 
145 kb B36 FII and FIB(pB171) 
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Figure 4. 7: SNP phylogenetic tree with the plasmid profiles of the ESBL carrier strains. 
The Figure displays the SNPs phylogenetic tree of the sequenced strains in this study with 
CFT073 strain as a reference. The plasmid profiles of the ESBL carrier strains (*) are displayed 
where the open circles represent the different plasmid sizes detected by S1 PFGE while the 
filled circles describe the different replicons identified by the Plasmid Finder web tool. 
Bacteraemia strains labelled red while UTI strains are blue. 
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Figure 4.7 shows the ESBL encoding plasmids were diverse among the thirteen ESBL carrier 
strains, containing 7 different sized plasmids with different backbones consisting of 
combinations of IncF replicons. Figure 4.7 illustrated more clearly the similarity between five 
(B10, B29, B73, B84, U76) of the seven strains identified in sections 4.3.1 and 4.3.2 earlier as 
they carry a plasmid of the same size and IncF replicon, a combination not found anywhere 
else in the tree. The remaining two strains (B36 and U42) shared a 112 kb plasmid with the rest 
of the group but with different variants of the incompatibility region consisting of FII/FIA and 
FIB respectively.                     
 
4.3.6 Serum resistance profiles 
At this stage of the study no unique loci were identified specific either to the genomes of 
bacteraemia ST73 E. coli or ESBL carrier ST73 E. coli. Plasmid profiling also revealed diverse 
plasmids carried by ST73 E. coli of the two clinical groups. Serum resistance was then 
investigated with the aim of identifying a phenotype specific for the bacteraemia or ESBL 
positive ST73 E. coli. The ability to resist complement mediated killing reflected by the serum 
resistance properties is an important virulence determinant for ExPEC in UTI and bacteraemia 
infections (Buckles et al., 2009; Miajlovic et al., 2014). All twenty-two selected strains were 
tested for their ability to survive the bactericidal effect of normal human serum after three hours 
incubation at 37ºC. The results are displayed in Figure 4.8. We noticed that all strains were 
resistant to the killing effect of normal human serum which calls for further investigation. 
Serum resistance properties of UTI causing ExPEC are well investigated in the literature and 
provided strong evidence for the role of O Antigens, Capsule, lipopolysaccharide (LPS), outer 
membrane proteins, enterobacterial common antigen (ECA) and colonic acid (Buckles et al., 
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2009; Phan et al., 2013; Miajlovic et al., 2014; Sarkar et al., 2014). A comprehensive study 
was performed by Phan et al. in 2013 to identify all the genes required to produce resistance to 
human serum in the E. coli ST131 strain EC958. The study utilized transposon directed 
insertion site sequencing (TraDIS) and fifty-six mutants were found associated with serum 
resistance with different significance. The main significant genes for serum resistance defined 
by the study were involved in O antigen biosynthesis (rmlA), lipid A core biosynthesis and 
LPS (waaA, rfaA, nag and pgm), biosynthesis of ECA (wecA), colonic acid biosynthesis (wcaF 
and fbp) and outer membrane proteins (tolA, tolQ and lpp). 
The above genes were investigated for their presence in the genome of our ST73 reference 
strain CFT073 which is well documented as being a serum resistant prototype isolated from 
the blood of uroseptic patient (Miajlovic et al., 2014). Although serum resistance mechanisms 
are not required to be present at the same time in a single bacterium to confer resistance (Cross 
et al., 1986; Phan et al., 2013), all the genes mentioned above were found in the reference 
genome CFT073. More importantly, when this group of genes was investigated in our 
sequenced ST73 strains from the clinical samples of UTI and bacteraemia, all of them were 
found in the genomes with no exception. Furthermore, another well documented serum 
resistance mechanism is a major outer membrane protein encoded by traT which is harboured 
on large IncF plasmids (Moll et al., 1980; Montenegro et al., 1985; Koga et al., 2014). This 
traT gene was screened as part of the VAGs screening multiplex PCR (section 3.3.5) but was 
found to be asbent from B14, B102 and U24. 
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Figure 4. 8: Serum resistance properties of the sequenced ST73 E. coli isolates from UTI and Bacteraemia. The figure displays the viable 
count of the tested isolates at the start of the procedure (blue, T0) and after three hours incubation (red, T3). E. coli CFT073 was used as a 
resistant control strain and E. coli MG1655 as a sensitive control. 
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4.4 Discussion 
In the previous chapter, one hundred and forty unrelated clinical E. coli isolates from 
bacteraemia and one hundred and twenty five clinical E. coli isolates from UTI were collected 
from Nottingham University hospital in a five month period of 2011. Compared to the UTI 
population, the population structure of bacteraemia revealed a reduction in diversity with 
ST131, ST73 and ST95 the three dominant STs. The E. coli isolates of these dominant STs 
were highly associated with ESBL carriage and multiple drug resistance and no significant 
variation in their VAGs carriage. This has led to the conclusion that ESBL carriage and MDR 
provided a selective advantage for these strains to emerge as successful dominant bacteraemic 
isolates (Alhashash et al., 2013). To further investigate this hypothesis, twenty-two randomly 
selected ST73 E. coli strains from clinical samples of bacteraemia and UTI with different ESBL 
carriage profiles were sequenced. A SNP based phylogenetic tree was obtained and revealed a 
heterogeneous group of ST73 E. coli isolates reflected by a total of 15278 high fidelity SNPs 
between them. The ST73 E. coli strains from bacteraemia and UTI did not cluster and were 
randomly distributed throughout the tree, which ruled out the presence of a specific outbreak 
strain. Seven ESBL positive E. coli strains, five from the bacteraemia samples (B10, B29, B36, 
B73 and B84) and two from UTI samples (U42 and U76) grouped together on one side of the 
tree and were further investigated by measuring the number of SNPs between them. They 
differed by 416 to 989 SNPs which indicates that they are distantly related ruling out recent 
transmission or linkage between cases. This finding of our local E. coli ST73 isolates is counter 
to the picture with the globally disseminated clone of E. coli ST131. Although collected from 
disperse geographical locations worldwide and different clinical sources, whole genome SNP 
phylogenetic analysis of these ST131 E. coli isolates reveal little diversity and clustering under 
a single lineage or sublineage (Price et al., 2013; Petty et al., 2014). Furthermore the SNP 
analysis between two clades of 85 ST131 E. coli isolates from a global data set were 
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distinguished only by 2,900 SNPs (Petty et al., 2014). In contrast, the analysis of the current 
study of a local 22 clinical E. coli ST73 isolates were distributed around the phylogenetic tree 
and the high diversity is confirmed by 15,278 SNPs between them. Before the recognition of 
the globally disseminated MDR E. coli ST131 (Price et al., 2013; Petty et al., 2014), our 
pathogen research group investigated the E. coli population in UTI in the region and ST131 E. 
coli isolates were the dominant strains with the highest antimicrobial resistance and CTX-M-
15 carriage (Clark et al., 2012). Ten unrelated isolates of these ST131 E. coli from the hospital 
and the community samples were sequenced. SNP based phylogeny of the strains against the 
ST131 reference strain NA114 displayed clear clustering where only 1324 SNPs were found 
between them and strain specific SNPs were as low as 10 to 60 SNPs, which confirms the 
circulation of the pandemic clone of E. coli ST131 (Clark et al., 2012). This a clear contrast to 
the local dominant CTX-M-15 positive E. coli ST73 isolates investigated in this project.           
 
For the purpose of our study, comparative genome analysis of all twenty-two sequences of 
ST73 E. coli strains from the clinical samples of bacteraemia and UTI was performed to 
investigate whether there are bacteraemia specific loci present or absent which define the 
strains and contribute to their passage and prevalence as a bacteraemic group other than being 
ESBL carriers. No genomic regions or unique loci were identified specific to the bacteraemia 
strains. The pangenome analysis showed a very heterogeneous population where the accessory 
genome represents almost 50% of the pangenome. In contrast, monomorphic genomes analysis 
can produce a core genome representing up to 80% of the pangenome, a result obtained by 
analysis of six strains of pathogenic Streptococcus agalatiae (Tettelin et al., 2005). No ctx-m 
genes were identified in the stringent option bacteraemia specific loci analysis but this can be 
explained since two of the bacteraemia strains were ESBL negative and they may not be from 
UTI origin associated with ESBL carriage. Causes for E. coli bacteraemia other than UTI 
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origins are documented in the literature such as trauma, burns, respiratory infection, intra-
abdominal infections, soft tissue infections, surgical wounds, intra-venous catheters and 
mechanical ventilators (Russo and Johnson, 2003; Rodriguez-Bano et al., 2008; Wu et al., 
2011). Indeed, when the less stringent conditions were used in the analysis ESBL and plasmid 
regions were identified as associated. The two comparative genome analyses, the high 
resolution phylogeny and pangenome analysis, clearly confirmed that the increased number of 
bacteraemic ST73 E. coli and the increased ESBL carriage of these bacteraemic ST73 E. coli 
are not a result of a sudden expansion of a successful clone as observed with ST131 (Price et 
al., 2013).    
 
The importance of serum resistance as a mechanism in establishing disease in UTI and 
bacteraemia by ST73 E. coli was emphasised as all twenty-two sequenced strains were serum 
resistant. Carriage of the significant serum resistance genes was also confirmed in all the 
sequences. A parallel study was performed in our research group to investigate urosepsis by E. 
coli (McNally et al., 2013). Isolates of E. coli from UTI of five patients were collected and 
compared to E. coli isolates collected from the blood of the same patients when they developed 
bacteraemia. All the strains from UTI and bacteraemia belonging to the same patient were 
found to be of the same sequence type except for one patient with three different strains. When 
serum resistance phenotypes were tested, there was no significant difference in the sensitivity 
to human serum between isolates from blood and urine of the same patient. Furthermore, the 
strains belonging to ST73 complex were also found to be serum resistant. Another study by our 
group found that all the ST131 E. coli isolates from UTI and bacteraemia were highly serum 
resistant (Alqasim et al., 2014). This and the results from the current study support the 
association of serum resistance with ST73 E. coli in general and with other dominant clinical 
STs. 
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As there was no association found between specific genomic regions or loci with bacteraemia, 
our focus was turned to investigate the ESBL carrying plasmids in our sequenced ST73 strains. 
S1 PFGE revealed the presence of diverse plasmids distributed between our strains in terms of 
the number of plasmids present and their sizes. When the plasmid types were determined by 
Plasmid Finder tool, all the plasmids were of IncFIA, IncFIB and IncFII which are well 
documented as being associated with CTX-M carriage and multiple drug resistance (Karisik et 
al., 2006; Villa et al., 2010; Carattoli, 2013). In addition to their replicons, these IncF plasmids 
have F transfer region for conjugation and promote their own transmissibility, which explains 
their dissemination (Johnson and Nolan, 2009). One particular CTX-M resistant plasmid was 
identified (FII\FIBAP001918, 112 kb) and matched between five strains, four from 
bacteraemia (B10, B29, B73 and B84) and one from UTI (U76) with similarity in their SNP 
phylogeny. This may suggest the circulation of this small group taking in consideration the 
different collection time between them and clinical source but requires further strain collection 
and sequencing to confirm. There is a noticeable distribution of plasmid types across opposite 
ends of the phylogenetic tree (Figure 4.7) where similar plasmids are shared with relatively 
close strains. A similar conclusion was suggested in Enterotoxigenic E. coli (ETEC) (Shepard 
et al., 2011; von Mentzer et al., 2014). In fact, a very recent study was conducted investigating 
the plasmid role in the evolution of ST131 E. coli sublineages which demonstrated that many 
lineages acquired a particular plasmid which was then spread in a clonal lineage (Lanza et al., 
2014) in a way similar to the evolution of the H30-Rx clone (Price et al., 2013). 
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Our investigation revealed that at the phylogenetic level, ST73 E. coli from bacteraemia and 
UTI are a diverse group not a successful circulating clone like ST131. At the gene content level, 
there was no bacteraemia specific loci associated with the bacteraemia ST73 E. coli, there was 
no ESBL positive specific loci associated with the ESBL carrying ST73 E. coli and the core 
genome was 50% of the pangenome genome which is different from the ST131 pandemic clone. 
Furthermore, at the plasmid level, diverse sizes and types of plasmids are distributed among 
the ESBL positive ST73 E. coli . This, in addition to displaying a highly serum resistant 
phenotype, leads to the conclusion that the increased number of ST73 E. coli isolates observed 
in the bacteraemia population and the increased ESBL carriage of these strains is totally a 
random event and that any ST73 E. coli can acquire a plasmid and become a successful 
bacteraemic strain.         
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Chapter 5 
Conclusions and Future directions 
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5.0 Conclusion and future directions 
The increase of bacteraemia caused by E. coli infection is associated with increased ESBL 
carriage and multidrug resistance, and has become a major health concern worldwide. Hence, 
identifying the E. coli bacteraemia population structure is of great importance. This PhD project 
aimed to identify and characterize the population of E. coli causing bacteraemia in terms of 
antibiotic susceptibility, ESBL and virulence associated genes (VAGs) carriage and analysis 
of the population structure using MLST. To put the E. coli bacteraemia population in context, 
the bacteraemia E. coli population was compared to a concurrent E. coli population isolated 
from UTI. In total 140 E.coli clinical isolates from bacteraemia and 125 clinical E. coli isolates 
from UTI were collected between March and July 2011 from Nottingham University Hospital 
(NUH). 
 
In general, an increased level of antibiotic resistance was observed in  the bacteraemia E. coli 
population when compared to the UTI E. coli isolates. In particular, a significantly higher 
resistance to ciprofloxacin and cefradine was observed in the bacteraemia E. coli population. 
This requires attention, as resistance to these antibiotics are associated with drug misuse by 
outpatients and increased prescription (Cooke et al., 2010; Sahuquillo-Arce, et al., 2011). More 
importantly, multidrug resistant E. coli were significantly more common in the bacteraemia E. 
coli population compared with the UTI E. coli. This multiple drug resistance, observed in the 
bacteraemia E. coli population, was associated with significantly higher ESBL carriage (CTX-
M, OXA and SHV) than the UTI E. coli isolates. This is of great concern as ESBL positive 
bacteraemic E. coli are reported to be associated with increased mortality (Cooke, et al., 2010; 
Sahuquillo-Arce, et al., 2011). 
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The carriage of virulence associated genes (VAGs) was screened in both the bacteraemia and 
UTI populations. Both populations displayed high proportion of carriage of fimH, fyuA, 
kpsMTII, PAI and traT, which are well described ExPEC associated virulence factors (VFs) 
(Bien et al., 2012). A significantly higher number of genes encoding iron acquisition system 
protein (iutA) and P fimbriae adhesin (papA, papEF, papG allele II and papG allele II,III) were 
observed in the bacteraemia E. coli. This was expected, as aerobactin siderophore (iutA) is a 
bacteraemia associated VF and P fimbriae is essential for upper UTI infections (Ron, 2010; 
Bien et al., 2012). On the other hand, S fimbriae which is encoded by the sfaS gene was present 
significantly more frequently in the UTI isolates. S fimbriae is associated with upper UTIs and 
pyelonephritis (Johnson and Stell, 2000; Jacobsen et al., 2008). As it is beneficial for the urine 
E. coli strains to attach to the kidney epithelium and cause disease, we could argue that loss of 
S Fimbriae by the bacteraemia E. coli strains is also beneficial as they are not confined to the 
kidney and are free to gain access to the blood stream.       
 
The population structure of the bacteraemia and UTI E. coli isolates was determined using 
MLST. The UTI E. coli population was found to be genetically diverse, consisting of a total of 
63 sequence types (STs) with almost equal distribution of the common STs. The most prevalent 
STs were ST73 (12.3%), ST131 (7.2%), ST69 (7.2%) and ST95 (4.8%). This indicated a 
change in the structure of the UTI E. coli population compared to the previous work by our 
group where ST131 complex most prevalent (Croxall et al., 2011).  The MLST results revealed 
that there was less genetic diversity in the bacteraemia population when compared to the UTI 
population. Within the bacteraemia population there were  three dominant STs that represented 
48% of the total isolates in the population. ST131 was the most dominant (21.4%) followed by 
ST73 (17.1%) and ST95 (9.2%). The increased prevalence of ST131 in the bacteraemia 
population warrants extra attention and molecular testing for identification purposes is advised 
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before prescribing antibiotics, as these strains are  associated with ESBL carriage and multidrug 
resistance.   
 
To understand the decreased genetic diversity in the bacteraemia population, when compared 
to the UTI population, comparisons were carried out to identify any variation in the carriage of 
ESBL and VAGs. This comparison revealed that there was a significant association between 
ESBL carriage and the bacteraemia STs, with 51.7% of the bacteraemia STs ESBL positive 
compared to only 30.1% of the UTI STs. The dominant bacteraemia STs (STs 131, 73 and 95) 
presented with a high proportion ESBL carriage, with a significantly higher ESBL carriage 
found in the bacteraemia ST73 isolates (50%), when compared to the UTI ST73 isolates (18%). 
In contrast, there was no significant difference observed for VAG carriage, which were equally 
distributed between the E. coli isolates from clinical bacteraemia and UTI samples. Attempts 
of assigning a set of VAGs specific to bacteraemia STs, which could explain a reason for their 
dominance, failed to identify any loci significantly associated with those dominant STs.  
 
Our findings revealed a strong association between multiple drug resistance due to ESBL 
carriage and the decrease in the genetic diversity of the bacteraemia population. ESBL carriage 
may provide a selective advantage for the success and progression of the bacteraemia isolates. 
Further genomic analysis was needed to identify any other factors that could explain the 
favoured selection for the dominant bacteraemia STs. This genomic analysis would also enable 
the identification and analysis of the diversity across the genome. Because of the fact that E. 
coli ST131 is a well-defined pandemic circulating clone (Johnson et al., 2013; Price et al., 2013; 
Petty et al., 2014), we aimed to investigate if this clonlity is observed in other dominant multi 
drug resistant (MDR) STs. We elected to genome sequence and analyse the poorly defined 
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ST73 clinical E. coli isolates for the purpose of our project. To our knowledge, comparative 
genome analysis specific to ST73 E.coli isolates from two contemporaneous clinical samples 
are lacking in the literature. Twenty two ST73 E. coli isolates from UTI and bacteraemia were 
selected (10 ESBL positives from bacteraemia, 2 ESBL negatives from bacteraemia, 3 ESBL 
positives from UTI and 7 ESBL negatives from UTI), which represent the ratio of positive to 
negative ESBL carriage in the two populations. This genomic analysis was targeted at 
determining  the phylogenetic relationship between the strains and identifying the presence or 
absence of loci specific for both bacteraemia  and ESBL carriage. Plasmid profiling was also 
performed to identify presence or absence of a successful circulating drug resistance plasmid. 
 
The high resolution phylogenetic tree representing the twenty two ST73 E. coli isolates 
revealed that the isolates were genetically diverse and there was no specific grouping according 
to the clinical source. This indicates that the increased prevalence of ST73 isolates the 
bacteraemia and UTI population is not due to the circulation of a successful clone, as was 
previously the case with ST131 in the same geographical region (Clark et al., 2012). When the 
SNP distances were determined, the high heterogeneity of the twenty-two genome sequences 
was confirmed, with a total number of 15,278 SNPs and the closest strains ranging from 416 
to 989 SNPs difference. In comparison ST131 from the UTI population observed previously in 
the region by our group (Clark et al., 2012) had 1324 SNPs between them and strain specific 
SNPs ranged between 10 and 60 only. It is clear that our high resolution phylogeny is 
completely different from the globally identified pandemic ST131 subclone H30Rx (Price et 
al., 2013; Petty et al., 2014). Large numbers of ST131 E. coli isolates from global geographic 
locations and different clinical sources are found to cluster phylogenetically in a single lineage 
or closely related subclades with few SNPs between them (Price et al., 2013; Petty et al., 2014). 
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In contrast, our ST73 E. coli isolates showed high level of diversity presented by heterogeneous 
phylogeny and 15278 high fidelity SNPs between local 22 strains.    
  
Comparative genome analysis of genomic sequences of all the twenty two ST73 E. coli from 
the bacteraemia and UTI clinical samples were performed using the Gegenees software (Agren 
et al., 2012). The comparative genomic analysis was carried out with the aim of identifying 
specific loci associated with the bacteraemia isolates and the ESBL positive isolates. No unique 
loci or genomic regions were found in the bacteraemia isolates. This indicates that bacteraemia 
ST73 E. coli isolates do not carry specific genomic loci which make them more likely to cause 
bacteraemic, therefore in theory any UTI ST73 E. coli strain can cause bacteraemia. Similarly, 
no unique loci or genetic regions were found specific to all the ESBL carrying isolates from 
UTI or bacteraemia. This indicated that the acquisition of ESBL plasmid by ST73 E. coli 
isolates from bacteraemia and UTI is not due to genetic predisposition, but rather by a 
completely random event. The limitation to these conclusions is that they apply only to ST73 
isolates. A larger sample size of ST73 E. coli isolates from bacteraemia and UTI would further 
support our findings. Our investigation would be more informative and more conclusive if we 
broaden the field and analysed many different STs at the same time, perhaps including the low 
prevalent STs such as ST10 isolates which were found ESBL negative in the UTI population 
and ESBL positive in the bacteraemia. This will provide more understanding to what drives 
different STs to become successful pathogenic STs. 
 
Construction of a pangenome for our ST73 data set confirmed the high level of genomic 
variation of the ST73 E. coli isolates. The pangenome revealed that the accessory genome, 
which encodes for the strain diversity and selective advantages for virulence factors, antibiotic 
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resistance and niche adaptation (Tettelin et al., 2008), accounted for about 50% of the 
pangenome (Figure 4.5). The plasticity and mosaic characteristics of the ST73 reference 
genome CFT073 E. coli is well documented in the litrature (Welch et al., 2002). Nevertheless, 
these studies produced core genomes of only 50 to 60% of the pangenome of CFT073 E. coli; 
this is a result of the inclusion of other distant pathotypes, such as intestinal pathogenic E. coli 
and commensal E. coli isolates (Lloyd et al., 2007; Rasko et al., 2008;). To our knowledge, our 
project produced for the first time a pangenome for isolates from the same ST of E. coli isolated 
from two clinical sources from the same geographical region and over the same time period 
and yet the genomic contents were very diverse, which is completely different to the 
monomorphic genomic characteristics of ST131 (Clark et al., 2012; Price et al., 2013). These 
results were not successful in identifying genomic traits that can be used to differentiate 
between the bacteraemia and UTI isolates. To identify a defining characteristic future work 
may have to investigate variation in gene expression, whilst isolates are exposed to the two 
clinical environments.  This future work could be carried out using expression studies such as 
RNA-sequencing, which could identify if a difference exists between the bacteraemia and UTI 
isolates, or between the ESBL plasmid positive and negative isolates.                            
 
Plasmid profiles of all the ESBL positive ST73 E. coli were determined and diverse plasmids 
were obtained. This indicated that there was no circulation of a particular resistance plasmid. 
All the plasmids detected in our study were typed to IncFIA, IncFIB and IncFII, which are 
associated with multiple drug resistance and CTX-M carriage. (Karisik et al., 2006; Villa et al., 
2010; Carattoli, 2013). These types of plasmids can promote their own transmission by their F 
transfer region through conjugation, which may explain the presence of similar plasmids shared 
by different strains in our sample. One plasmid was of particular interest which have the size 
and the same type named (FII\FIBAp001918) by the plasmid finder tool (Carattoli et al., 2014), 
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was found carried by five closely related strains; 4 from bacteraemia (B10, B29, B73, and B84) 
and one from UTI (U76), located on one side of the phylogenetic tree (Figure 4.7). This plasmid 
warrants further characterization and analysis by sequencing. Taking in consideration that this 
plasmid was shared between isolates from different clinical sources, analysis may reveal the 
start of a successful circulating group of isolates in a clonal lineage. Sequencing and Analysis 
of the other ESBL plasmids in this group may identify specific VAGs carried on these plasmids, 
which may have a role in their increased prevalence in bacteraemia isolates.   
 
This project reported an increase and dominance of ST73 E. coli in the urine population 
compared to previous reports (Gibreel et al., 2011; Clark et al., 2012). This project also revealed 
that ST73 E. coli was a dominant ST in the bacteraemia population. Our study reported that 
this increase of bacteraemic ST73 E. coli is highly associated with increased ESBL carriage 
and multi drug resistance. The comparative genome analysis showed that there were no unique 
loci specific to the bacteraemia ST73 E. coli and no unique loci specific to ESBL carrying 
ST73 E. coli originating from blood or urine. Furthermore all ST73 E. coli appear to have 
intrinsic ability to be serum resistant. In conclusion, the evidence gathered from this project 
infers that it is possible for any ST73 E. coli from UTI to potentially acquire an ESBL resistance 
plasmid and become highly pathogenic or bacteraemic, both of which have associations with 
increased mortality. This project provided the latest comprehensive snapshot of the population 
structure of clinical E. coli isolates from UTI and bacteraemia clinical samples and offered new 
insights on the adaptation of a common sequence type to become a dominant successful 
pathogen.    
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6.0 Appendix 
6.1 Full scanned copy of the publication which contained information and 
data in this PhD thesis: 
 
Title:  
Multidrug-Resistant Escherichia coli Bacteremia 
 
Authors:  
ALHASHASH, F., WESTON, V., DIGGLE, M. AND MCNALLY, A. 
 
Journal: 
(2013). Emerg. Infect. Dis. 19 (10): 1699-1701 
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6.1 Supplementary information for Chapter Four – (Comparative genome 
analysis) 
6.2 Sequences assembly by Velvet software 
All the raw sequencing data of the selected twenty two ST73 E.coli isolates were received from 
Exeter Sequencing Service in a FASTQ file format. FASTQ files are common text files which 
include the sequencing reads of the nucleotides and their associated quality scores (Cock, et al., 
2010). Velvet software was used to assemble the sequences (Ebi.ac.uk/~zerbino/velvet, 2014).  
Illumina sequencing produces short reeds and the genome assembly requires piecing together 
these random reads into contiguous sequences or contigs (Zerbino and Birney, 2008). The size 
of our FASTQ files were large of about 1.9 Gigabytes (gb) in average as it included a lot of 
information about the nucleotide in the sequence. Scripts were used to shorten and shuffle the 
forward and reverse FASTQ files of each isolate into a Velvet recognizable version. Velvet is 
a de Bruijn graph assembler used for the production of de novo assembled genomes, which 
means it assembles the genomes without the use of a reference genome of a closely related 
strain (Swain, et al., 2012). Velvet works in two parts. First, the reads were converted into k 
nucleotides words or k-mers in a statistical table containing all the nucleotides present in the 
sequence with their quality information (Zerbino and Birney, 2008). This was obtained by 
running velvet h script of the software with k-mer size of 31. Second, the overlapping k-mers 
and the de Bruijn graph produced by velvet h were pieced together into long sequences or 
contigs to make the assembled genome. This was obtained by running velvet g script of the 
software with expected coverage the bps of 75 fold and 8 reads cut-off parameters. The output 
file of Velvet software is a FASTA format which is simply a text file containing the nucleotides 
sequence of the genome without any annotations. Assembled genome sequences were obtained 
for all the twenty two ST73 E. coli isolates and were used for further analysis. 
De novo Velvet assembly was performed using a script involving these command lines: 
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Head -n 20000000 sampleR1.fastq > sampleshort.fastq 
Head -n 20000000 sampleR2.fastq > sampleshort2.fastq 
Perl shuffleSequences_fastq.pl sampleshort.fastq sampleshort2.fastq sampleinput.fastq 
Velveth: sample assem 31 -shortPaired -fastq sampleinput.fastq 
Velvetg: /home/alan/Desktop/sample assem -exp_cov 75 -cov_cutoff 8 
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6.3 Post assembly genome improvement toolkit (PAGIT) 
PAGIT software produces a high quality sequence from de novo assembled genomes by 
utilizing a number of sub programmes namely ABACAS, IMAGE, iCORN and RATT in 
accordance of a closely related reference strain (Swain, et al., 2012). In the PAGIT assembly 
CFT073 E. coli genome sequence (NCBI Reference Sequence: NC_004431.1, genome size is 
5231428 bps) was used as a reference genome because it belonged to sequence type ST73.  The 
forward and reverse FASTQ files in addition to the FASTA file obtained from Velvet were 
also included. The unguided contigs produced from Velvet were reordered by ABACAS 
programme according to the reference genome and any sequences which are not mapped with 
reference such as plasmid sequences are reordered at the end. IMAGE programme reduced the 
gaps in the assembled genome by mapping the FASTQ files against the contigs (Swain, et al., 
2012). Two important parameters of the quality of an assembled genome is a reduced total 
number of contigs and an increased N50 (which is the median contig length) up to 50 kb or 
more (Zerbino and Birney, 2008). IMAGE programme has managed to close the gaps and 
reduce the number of contigs in the original velvet assembly genomes from thousands to 
hundreds, and has increased the N50 from thousands to tens of thousands. Details of a much 
improved assembled genomes of all the twenty two ST73 E. coli isolates after PAGIT assembly 
are described in Table 4.2. In addition, errors in the assembled genome such as insertions, 
deletions or substitutions were corrected by iCORN programme through mapping against 
original sequencing reads. Finally, RATT transferred the annotations from the reference 
genome CFT073 to the final assembled genome (Swain, et al., 2012). The high quality genome 
assembly by PAGIT was performed on all the selected twenty two ST73 E.coli isolates. The 
final output file of PAGIT assembly was an EMBL file which is an annotation file format 
similar to GENBANK (GBK) file. A final FASTA file for each of the sequenced isolates was 
obtained from their final EMBL file through Artemis software (Carver, et al., 2012). 
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The PAGIT assembly script was written by Dr. Alan McNally. Firstly, (velv.fa), 
(strainfor.fq), (strainrev.fq), (reference.fasta) and (reference.embl) files were moved into 
PAGIT (or PAGIT.V1.64bit) folder. Now you open PAGIT folder and double click on 
dorun.sh file and choose display, and on top you write the exact strain name, the velv.fa 
name, the reference.fasta name and the reference.embl name and then save. Open the 
terminal type cd and run PAGIT from the terminal using these command lines: 
cd Desktop 
cd PAGIT (or PAGIT.V1.64bit) 
source sourceme.pagit 
./dorun.sh 
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6.4 Annotation of sequenced  
Prokka software is a rapid more accurate unguided annotation tool compared to transfer 
annotation softwares which produce errors as they force the transfer of annotations (Seemann, 
2014). Only FASTA files of the assembled genomes are required to start the Prokka script 
where it utilizes a built in database to annotate the genome and produces output files in GFF 
and GENBANK (GBK) formats which are compatible annotation formats ready for further 
analysis (Seemann, 2014). All the selected twenty two ST73 E. coli isolates genomes where 
annotated by Prokka software. 
Prokka annotation was performed using the command line: 
./prokka --outdir sample ID _prokka --genus Escherichia --locustag sample ID sample ID.fasta 
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6.5 Single nucleotide polymorphism (SNP) based phylogeny 
 
6.5.1 Alignment of sequenced genomes 
All the twenty two sequenced ST73 E. coli isolates were aligned against E. coli CFT073 as a 
reference genome using SMALT software which is developed and optimized by Wellcome 
Trust Sanger Institute (Sanger.ac.uk, 2014). SMALT provides a more accurate alignment of 
paired end sequencing reads produced by Illumina, Roche 454 or ABI Sanger compared to 
other alignment programmes such as BWA and BOWTIE (Wellcome Trust Sanger Institute, 
2014a). SMALT alignment process involves first forming an index table of the reference 
genome consisting specific length words or hashing with equidistant spaces, then sequence 
reads are mapped against the hash index (Wellcome Trust Sanger Institute, 2014b). The input 
files used for SMALT software were the FASTA file of the reference genome E. coli CFT073 
and the two FASTQ files of sequences for each strain. The words length used in the index was 
seventeen with equidistant steps of two.  Each of the twenty two ST73 strains were mapped by 
SMALT software individually and the output file for each was obtained in a SAM file format. 
SAM files created by SMALT were large in size containing all the statistical information of 
the alignment including the position of each single read against the reference, the quality score 
of the bases and the quality score of the reads. 
SAMtools software was used to extract the required information from SAM files generated by 
SMALT in the previous step. SAMtools is a software used to manipulate the data in SAM 
format files such as indexing, merging, sorting and other post processing requirements (Li et 
al., 2009). SAMtools scripts were applied on the SAM files to produce an index from the 
reference genome, generate BAM files which are readable by other programmes and sorting 
the BAM files information of the position of the reads according to the reference genome index 
with their specific read scores. Since we aim to obtain high mapping with high fidelity SNPs, 
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SAMtools scripts were also used to remove duplicate sequences generated by the adapters 
during multiplex sequencing. A last and very important SAMtool script was used to pileup the 
reads against the reference genome to produce a BCF file format containing the base variants 
of the reads along with the number of bases and the quality scores in these variants or SNPs. 
This last SAMtools scripts also included a command to pipe the output BCF file into bcfTools 
programme with all the SNPs and their quality scores information. BCF files can be recognized, 
converted to VCF files or indexed by bcfTools software (Evolution and Genomics, 2011). VCF 
files were produced from BCF files by scripts of bcfTools software and piped into perl vcfutils 
to utilize a varfilter script with maximum likelihood of one hundered which removed SNPs 
reads which were very low. These VCF files contained all the SNPs data for each strain against 
the reference genome E. coli CFT073 and they were filtered to obtain high fidelity SNPs using 
scripts performed by Alan McNally at NTU. The filtering criteria for obtaining high fidelity 
SNPs based phylogenetic tree was removing multiple alleles, removing reads with of quality 
scores of less than thirty, removing SNPs reads which were less than eight and most 
importantly the allele frequency was determined to be 75%. 
/Desktop/smalt-0.5.8$ ls 
./smalt_x86_64 index -k 17 -s 2 CFT073index CFT073.fasta  
./smalt_x86_64 map -f sam -o B14.sam CFT073index B14_R1.fastq B14_R2.fastq 
samtools faidx CFT073.fasta 
samtools view -bS -t CFT073.fasta.fai -o B14.bam B14.sam 
samtools sort B14.bam B14.sort 
samtools rmdup B14.sort.bam B14.out 
samtools mpileup -ugf CFT073.fasta B14.out | bcftools view -bvcg - > B14.raw.bcf 
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bcftools view B14.raw.bcf | perl Vcfutils.pl varFilter -D 100 > B14.vcf 
bgzip B14.vcf 
tabix -p vcf B14.vcf.gz 
 
6.5.2 Construction of SNPs based phylogenetic tree 
VCF files containing SNPs information of the all the twenty two sequenced ST73 E. coli strains 
obtained in the previous step were filtered as described above using scripts applied by Alan 
McNally at NTU and converted to FASTA file formats. Another FASTA format file of all the 
SNPs was generated from VCF files with removing off the common SNPs which were present 
in all the strains regardless of the reference genome in order to improve measurements of SNPs 
distances. The individual SNPs FASTA files were concatenated into one SNPs FASTA file 
and was viewed in SeaView software. SeaView programme is a sequence alignment editor and 
viewer of many alignment file formats such as NEXUS, CLUSTAL, MASE, MSF, FASTA 
and PHYLIP (Gouy et al., 2010). The SNPs FASTA files were opened in SeaView software to 
view the SNPs and saved as PHYLIP file format which the only format recognizable by the 
phylogenetic tree generating software called RAxML-HPC or randomized axelerated 
maximum likelihood for high performance computing (Stamatakis, 2006). The RAxML-HPC 
script was implied to produce a 100 phylogenetic trees with rapid bootstrapping which is a 
statistical method used to place confidence in repeated sampling or in this case the 100 
phylogenetic trees (Felsenstein, 1985). RAxML-HPC script used also applied (GTR) or general 
time reversible model and gamma distribution which is a nucleotide substitution model for 
DNA evolution in which all the bases in the bacterial genome are considered unbiased and can 
mutate to produce sense and non-sense SNPs unlike the eukaryotic genome (Rodriguez et al., 
1990). The last step in RAxML-HPC script was set to imply the maximum likelihood statistics 
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which estimates or infer the maximum likelihood of the generated phylogenetic trees to be true 
given the different evolutionary parameters (Felsenstein, 1981). The output file obtained from 
RAxML-HPC was best tree in RAxML format and it was used to view the SNPs based 
phylogenetic tree using Figtree software (tree.bio.ed.ac.uk/software, 2014). The phylogenetic 
tree was viewed and saved into the phylogenetic file format called NWK file. 
RaxML maximum likelihood phylogeny was performed using the command line: 
raxmlHPC -f a -m GTRGAMMA -x 12345 -# 100 -s Alan_ Escherichia _align.phy -n Alan _ 
Escherichia _raxml 
 
6.5.3 Measurement of pairwise distance 
The SNPs FASTA files generated in section 4.2.7.3 were used to compute the number of base 
differences between the ST73 E coli strains using MEGA software (Tamura et al., 2013). 
Pairwise distance measurement was selected from the Distance menu and the number of SNPs 
were determined. A table was generated and exported as spreadsheet file for further analysis. 
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6.6 Comparative Genome analysis 
Whole genome comparisons were performed on all the twenty two ST73 E. coli from the 
clinical samples of bacteraemia and UTI using the software Gegenees (Gegenees.org, 2014). 
Gegenees software allows the comparative analysis on up to hundreds of complete or draft 
genomes by aligning fragments of all the genomes utilizing multithreaded blast approach. The 
alignment data can provide a phylogenetic view of the genomes, but more importantly for our 
study, it can be used to investigate the presence of genomic regions unique in a target group 
when compared to a background group (Agren et al., 2012). Gegenees software was also used 
to determine the core and pangenome. 
 
6.6.1 Investigation of bacteraemia and ESBL carrier specific loci 
Gegenees software was used to investigate the presence or absence of genomic regions or loci 
specific only to bacteraemia or to ESBL carrier strains of the sequenced ST73 E. coli. This was 
performed by utilizing the Fragmented all-all comparison option (Gegenees.org, 2014). First, 
all the twenty two GENBANK (GBK) files were imported in a new database in Gegenees 
software, FASTA file formats can also be used. Then, in the (Fragmented all-all comparison) 
widow, nucleotide comparison (BLASTN) was chosen with the highest resolution parameters 
for the alignment (200/100) which were 200 bps of sliding fragment window size and 100bps 
of progressive step size respectively. When the alignments and fragments comparison were 
performed and displayed, the bacteraemia strains were selected as target group against a 
background group of all the UTI strains in order to investigate for the presence of bacteraemia 
specific genomic regions or loci. The strain B134 was chosen as reference genome from the 
target group to refer the unique loci to with annotations. In the other test, all the ESBL carrier 
strains were selected as a target group from bacteraemia and UTI clinical samples against a 
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background group of ESBL absent strains in order to investigate ESBL carrier specific genomic 
regions or loci with B134 strain as a reference from the target group.       
 
6.6.2 Determination of core and pangenome 
An overview of the core and pangenome of all the twenty two ST73 E. coli strains was created 
by Gegenees software. All the genomes were fragmented then compared to each other and their 
BLASTN scores were determined. The pangenome was constructed progressively by analysing 
the fragments BLASTN scores and then each new unique fragment was deposited in the 
pangenome (Gegenees.org, 2014). In the (New pangenome) option, 1% threshold was selected 
for maximum distinctive selection of unique fragments. 
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6.7 Progressive Mauve alignment 
Progressive Mauve software is capable to successfully align multiple sequences of closely 
related strains even if they have suffered genome rearrangements, loss or gain by 
recombination (Darling et al., 2010). In the Figure below, the twenty two sequenced genomes 
of ST73 E. coli strains from clinical samples of bacteraemia and UTI are shown. Blocks of the 
same colour connected by a line are homologous while the difference in their sizes and 
sometimes their loss displays the variation between the strains. More noticeably are the large 
numbers of homologous lines at the end of the genomes which represent the plasmids 
sequences region with multiple crosses between them indicating high variations and 
rearrangement events in their sequences. 
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